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Autism spectrum disorder (ASD) is a complex heterogeneous neurodevelopmental
disorder characterized by alterations in social functioning, communicative abilities, and
engagement in repetitive or restrictive behaviors. The process of aging in individuals with
autism and related neurodevelopmental disorders is not well understood, despite the fact
that the number of individuals with ASD aged 65 and older is projected to increase by
over half a million individuals in the next 20 years. To elucidate the effects of aging in
the context of a modified central nervous system, we investigated the effects of age
on the BTBR T + tf/j mouse, a well characterized and widely used mouse model that
displays an ASD-like phenotype. We found that a reduction in social behavior persists into
old age in male BTBR T + tf/j mice. We employed quantitative proteomics to discover
potential alterations in signaling systems that could regulate aging in the BTBR mice.
Unbiased proteomic analysis of hippocampal and cortical tissue of BTBR mice compared
to age-matched wild-type controls revealed a significant decrease in brain derived
neurotrophic factor and significant increases in multiple synaptic markers (spinophilin,
Synapsin I, PSD 95, NeuN), as well as distinct changes in functional pathways related
to these proteins, including “Neural synaptic plasticity regulation” and “Neurotransmitter
secretion regulation.” Taken together, these results contribute to our understanding of
the effects of aging on an ASD-like mouse model in regards to both behavior and protein
alterations, though additional studies are needed to fully understand the complex interplay
underlying aging in mouse models displaying an ASD-like phenotype.
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INTRODUCTION
Autism spectrum disorder (ASD) is a heterogeneous neu-
rodevelopmental disorder characterized by varying degrees of
altered social functioning and engagement in repetitive, stereo-
typed behaviors accompanied by display of narrowed inter-
ests (American Psychiatric Association, DSM-V 2012). The
most recent surveillance data collected in 2008 by the Center
for Disease Control’s Autism and Developmental Disabilities
Monitoring Network indicates that approximately 1 in 88 chil-
dren has an autism spectrum disorder (CDC, 2010). The United
States Census Bureau in 2006 projected a doubling of the US pop-
ulation aged 65 and older by 2030. Assuming the life expectancy
of individuals with ASD is similar to that of the general popula-
tion, based on current prevalence rates in school aged children,
this population increase would result in a prevalence of approxi-
mately 700,000 individuals with ASD aged 65 in the next 20 years
(Piven and Rabins, 2011).
Abbreviations: BDNF, brain derived neurotrophic factor; BTBR, black and tan,
brachyuric; ASD, autism spectrum disorder.
Despite the population statistics indicating a significant num-
ber of aged individuals with ASD, studies that investigate the
effects of the neurodevelopmental disabilities including ASD, in
an aged physiological context are lacking. Due to the paucity and
limitations of studies and the expected increase in the aged indi-
viduals presenting ASD a multidisciplinary conference was held
in March 2010 to identify gaps in knowledge regarding older
adults with ASD. The panel concluded that descriptive stud-
ies of aging in humans and rodent models were needed (Piven
and Rabins, 2011). A limited number of human studies have
investigated the persistence of the ASD core deficits into adult-
hood (Ballaban-Gil et al., 1996; Seltzer et al., 2003; Shattuck
et al., 2007), childhood factors that are associated with prognosis
(Rumsey et al., 1985), and outcome studies (Rutter et al., 1967;
Howlin et al., 2004; Renty and Roeyers, 2006). Major findings
from these studies suggest that language development (Kanner
et al., 1972) and Intelligence Quotient (IQ) predicts outcome
(Lotter, 1974; Rumsey et al., 1985; Szatmari et al., 1989). The
ASD diagnosis persists with inconsistent findings about which,
if any, core deficits change (Ballaban-Gil et al., 1996; Piven et al.,
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1996; Seltzer et al., 2003), and that the adults with ASD remain
dependent on others (Rutter et al., 1967) even if they have a
normal IQ (Howlin et al., 2004). Despite persistent dependence
some studies found that individuals with ASD had improved
symptoms over time (Szatmari et al., 1995; Piven et al., 1996;
Seltzer et al., 2003). However, a few limitations hinder these
early studies of aging in ASD, including study individuals being
only 20–30 years old, small sample sizes, and an inability to
completely generalize the study findings given the heterogene-
ity of the population examined (Rumsey et al., 1985; Gillberg
and Wing, 1999; Fombonne et al., 2001; Howlin and Moss,
2012).
Given the heterogeneous nature of ASD, mouse models have
proven to be particularly useful and reliable in elucidating the
mechanism of these disorders (Crawley, 2007; Moy and Nadler,
2008). There are several approaches to ASD mouse models:
targeted gene mutations, defects in neurotransmitters or brain
regions, inbred strains, and models based on the comorbidity of
other human diseases with autism (Crawley, 2007). One strain in
particular, BTBR T+ tf/j, has been shown to be an especially rele-
vant animal model of ASD (Moy et al., 2007). Extensive behav-
ioral characterization of the BTBR (black and tan, brachyuric)
mouse model has revealed low sociability compared to wild-
type strains (Bolivar et al., 2007; Moy et al., 2007), resistance
to change (Moy et al., 2007; Moy and Nadler, 2008), increased
display of self-grooming behavior (Pobbe et al., 2010), display
of repetitive behaviors (Pearson et al., 2011), and reduced dis-
play of territorial scent marking (Wohr et al., 2011). Furthermore,
unusual vocalizations have also been extensively characterized in
BTBR mice (Scattoni et al., 2008, 2011), in addition to instances
of social avoidance and gaze aversion (Defensor et al., 2011).
While the autistic-like behavioral phenotype of the young male
BTBR mouse has been studied extensively, the effects of age on
this ASD-like mouse model have not been elucidated. As aged
human autistic tissue samples are limited and the BTBR mouse
model is well characterized and widely accepted, we selected this
mouse model to study the nature of the ASD phenotype in an
aged context. To enhance our understanding of the aged BTBR
mouse and to gain further insight into the effects of aging of
ASD, we followed our extensive behavioral characterization of
the aged BTBR mouse with quantitative proteomic analyses on
cortical and hippocampal tissues as these two brain regions have
been strongly associated with ASD (Mundy, 2003; Nadler et al.,
2006). We hypothesized that both the behavioral phenotype and
proteomic profile would be different between the aged ASD-like
mice [or mice with an abnormal central nervous system (CNS)]
and the aged wildtype mice (or mice with a presumed normal
CNS). Our results contribute to our understanding of the effects
of aging on an ASD-like mouse model, and it is our hope that
further research will enhance our understanding of aging in an
abnormal CNS.
MATERIALS AND METHODS
EXPERIMENTAL ANIMALS
All experimental animal procedures were approved by the Animal
Care and Use Committee of the National Institute on Aging,
National Institutes of Health. Male BTBR T+ tf/J mice (n = 8, 15
months of age) andmale control wildtype (WT) C57BL6J (n = 5,
15 months of age) were housed in the NIA animal facility on
a 12 h light and dark cycle from 6 am to 6 pm and received ad
libitum access to food and water throughout the duration of the
study. All behavioral testing described in detail below was per-
formed between the hours of 9 AM and 5 PM. Prior to behavioral
testing, animals were moved from the vivarium to an experimen-
tal room and given a minimum of 30min to habituate to the new
environment. Between each experimental animal, all apparatuses
were wiped downwith 70% ethanol followed by D. I. water to pre-
vent any scent retention that could possibly bias the performances
of later mice.
SOCIAL PREFERENCE ASSESSMENT
Social behavior was assessed using a three-chambered sociability
apparatus with a protocol modeled after previously established
methods (Crawley, 2007). In brief, animals were first habituated
for 10min to the three-chambered sociability apparatus (60 ×
40 × 22 cm, Stoelting, Wood Dale, IL) free of any stimuli and
returned to their home cage for a minimum of 30min. Prior to
the return of the experimental mouse to the chamber for testing,
another mouse of the same strain, age, and gender and an inani-
mate object both housed in identical wire mesh cylinders (15 cm
tall, 7 cm in diameter) were placed in opposing compartments of
the apparatus. Experimental animals were then returned to the
center chamber of the apparatus and were free to choose to inter-
act with either the mouse or object enclosed in the respective wire
mesh containers. Interactions were recorded for 10min and ana-
lyzed with ANY-Maze Video Tracking Software (Stoelting). A dis-
crimination index (DI) was calculated that takes into account the
relative exploration time spent with either the containedmouse or
object: (animal time/total time—object time/total time) × 100.
As socially-normal mice show a robust preference for another
mouse over an inanimate object, a high DI is reflective of socially-
normal behavior while a low DI is indicative of deficits in social
functioning.
NOVEL OBJECT PREFERENCE TEST
The novel object preference test was performed as described pre-
viously (Dere et al., 2007; Park et al., 2010). In brief, mice were
given 10min to explore a 25 cm2 opaque walled box with two
identical objects placed equidistant from each other in the cen-
ter of the box. After 10min of habituation to the two identical
objects was completed, animals were returned to their home
cages for a minimum of 30min. After the habituation task,
trained experimenters replaced one of the identical objects with
a novel object that had never been seen by the experimental
mouse. Experimental animals were then returned to the opaque
box and given 10min in which they were free to interact with
either the familiar or novel object. Both the habituation session
and testing session were videotaped and the animal’s behavior
automatically tracked by ANY-Maze Video Tracking Software
(Stoelting). Discrimination indices were again calculated: (novel
time/total time-same time/total time) × 100. A high discrimi-
nation index (DI) is indicative of an enhanced ability to pref-
erentially recognize the novel object, suggesting intact memory
functioning.
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FIGURE 1 | Social function, cognitive ability, general behavior, anxiety
and motor coordination in an aged ASD mouse model. Social preference
was assessed using a three-chambered sociability apparatus in aged male
BTBR T + tf/j mice and age-sex-matched control mice (A, B). Percentage of
time spent exploring both the contained inanimate object and the contained
mouse was measured for male BTBR (n = 8) and control mice (n = 5) (A). A
discrimination index (DI) was calculated (B) which represents the degree to
which experimental or control animals displayed a preference for exploring
the contained mouse over the contained inanimate object. Cognitive
functioning was assessed via the novel object preference task (NOP) (C, D).
Percentage of time spent exploring either a familiar or a novel object was
again measured for male BTBR (n = 8) and control mice (n = 5) (C) and a DI
was calculated (D) with a higher DI indicating an increased ability to discern a
novel object from a familiar object. Exploration of an open field apparatus was
assessed in male BTBR and control mice was measured with regard to the
following parameters: time spent exploring the peripheral or central areas of
the apparatus relative to the total amount of time spent exploring (E), total
distance traveled (F), number of ambulatory episodes (G), and number of
jumps (H). Exploration of the open field apparatus was repeated with a
Light/Dark insert add-on and relative time spent in either the light half or the
dark half of the chamber was recorded (I). General anxiety was assessed
using the elevated plus maze task. For both BTBR T + tf/j mice and age-and
sex-matched controls, relative spent in the closed vs. the open arm was
recorded as a percentage of total time (J). Finally, motor coordination was
assessed using a rotarod apparatus latency to fall was recorded in both BTBR
T + tf/j and control mice (K, n = 5). Data are expressed as means ± s.e.m.
Asterisks represent p-values as shown: ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001.
Statistical significance was measured using a Student’s t-test.
OPEN FIELD TEST
A generalized view of the behavioral characteristics of both
experimental and control mice was obtained via an open field
test performed as described previously (Holmes et al., 2002).
In brief, each mouse was placed in a square chamber approx-
imately 0.14m2 in size (Med Associates Inc, St. Albans, VT)
and given 10min to freely explore. Activity Monitor software
(Med Associates Inc) automatically recorded multiple parame-
ters over the duration of the 10min test. Individual data points
were then compiled and subsequently analyzed to produce the
following measurements: distance traveled, time spent in the
peripheral areas of the chamber, time spent in the center area
of the chamber, number of ambulatory episodes, and number of
jumping episodes. Relative time spent in the periphery vs. the cen-
ter was calculated for each mouse by dividing the time spent in
either the periphery or center by the total exploration time (600 s
for all animals).
LIGHT/DARK EXPLORATION TEST
The light-dark exploration test was performed as previously
described (Chadwick et al., 2011) as ameans to assess general anx-
iety behavior. The same square chamber used in the Open field
test was again used to complete the Light/Dark exploration test,
with the additional insertion of a dark chamber taking up 50%
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FIGURE 2 | Protein expression in wild type and BTBR mouse
cortex. Western blotting was performed using mouse cortical protein
lysates (A). Protein levels were measured in BTBR and control mice
with respect to the following proteins in the cortex: pro-BDNF (B),
mature BDNF (C), phospho-TrkB (D), total TrkB (E), Akt (F)
phospho-synapsin 1 (G), synapsin 1 (H) synaptophysin (I), PSD95 (J),
spinophilin (K), Neuronal cell marker NeuN (L). Data are expressed as
means ± s.e.m. Asterisks represent p-values as shown: ∗p < 0.05.
Statistical significance was measured using a Student’s t-test, n = 3
for each group.
of the area of the entire apparatus (Dark box insert for mouse
open field activity, Med Associates Inc). The dark chamber con-
tains a small arched entrance to allow mice to access the dark
environment; this entryway was placed toward the center of the
apparatus so mice could easily access it. Time spent in either the
light or dark compartment was automatically recorded by Activity
Monitor software (Med Associates Inc). Relative time spent in the
light chamber vs. the dark chamber was calculated for eachmouse
by dividing the time spent in either the light or the dark by the
total exploration time (600 s for all animals).
ELEVATED PLUS MAZE
General anxiety behavior was also evaluated using an elevated
plus maze test as described previously (Chadwick et al., 2011).
In brief, animals were given 5min to explore a plus shaped maze
raised approximately 36 cm off of the ground. Two of the arms
of the maze were enclosed on all sides; two arms remained open
for the duration of the test. ANY-Maze Video Tracking Software
(Stoelting) was used to record time spent in either the closed or
open arms of the apparatus and the relative time spent in the
closed or open arms was calculated by dividing the time spent
in either arm by the total exploration time (300 s for all animals).
ROTA-ROD TEST
Motor coordination was evaluated using an accelerating Rota-
Rod treadmill (Med. Associates, Inc) as described previously
(Bohlen et al., 2009). Briefly, mice were given two training ses-
sions on the spinning Rota-Rod apparatus on the day prior to the
testing day (the first trial was administered in the morning and
the second trial was administered in the afternoon). Each habitu-
ation training trial lasted 2min [4 revolutions per minute (rpm)].
On the test day, the mice were placed on the Rota-Rod, which
gradually accelerated from 4 to 40 rpm over a 5min time interval.
The test was performed twice per day and the latency to fall was
measured and averaged.
ANIMAL EUTHANIZATION AND TISSUE COLLECTION
Following completion of behavioral analyses, animals were euth-
anized via isoflurane overdose (Butler Animal Health Supply,
Dublin, OH) as described previously and in accord with approved
animal procedures (Chadwick et al., 2011). Bodyweight data was
collected immediately prior to euthanization for each animal.
Hippocampal and cortical brain tissues were snap frozen on dry
ice and stored at −80◦C until used for further analyses.
PROTEIN DIGESTION, iTRAQ LABELING ANDWESTERN BLOTTING
Protein digestion and iTRAQ labeling were processed
according to the iTRAQ protocol (iTRAQ Reagents—8plex:
amine-modifying Labeling Reagents for Multiplexed Relative
and Absolute Protein Quantitation, ABSciex). All tissue samples
(Hippocampus and Cortex; WT and BTBR) were prepared in
parallel throughout the labeling procedures. Briefly, 100μg
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FIGURE 3 | Protein expression in wild type and BTBR mouse
hippocampus. Western blotting was performed using mouse
hippocampal protein lysates (A). Protein levels were measured in BTBR
and control mice with respect to the following proteins in the
hippocampus: pro-BDNF (B), mature BDNF (C), phospho-TrkB (D), total
TrkB (E), Akt (F) phospho-synapsin 1 (G), synapsin 1 (H) synaptophysin
(I), PSD95 (J), spinophilin (K), Neuronal cell marker NeuN (L). Data are
expressed as means ± s.e.m. Asterisks represent p-values as shown:
∗p < 0.05, ∗∗p < 0.01. Statistical significance was measured using a
Student’s t-test, n = 3 for each group.
of protein in each condition was acetone precipitated and
resuspended in 20μL of iTRAQ dissolution buffer (0.5M tri-
ethylammonium bicarbonate (TEAB), ABSciex) containing 0.1%
ProteaseMAX detergent (Promega) to denature the proteins. The
sample was then reduced by adding iTRAQ Reducing Reagent
[Tris(2-carboxyethyl) phosphine (TCEP), ABSciex] to a final con-
centration of 5mM and incubated at 60◦C for 1 h. Subsequently,
the sample was alkylated with iTRAQ Cysteine-Blocking Reagent
(10mM methyl methanethiosulfonate (MMTS), ABSciex) for
10min at room temperature. The protein sample was then
digested with 5μg sequencing-grade trypsin (Promega) per
100μg protein at 37◦C overnight. Labeling of the samples with
iTRAQ 8-plex labels was performed at room temperature for
2 h. After labeling, the samples to be compared were mixed
and underwent an off-line strong cation exchange (SCX)
fractionation (ICAT Cation Exchange Buffer Pack, ABSciex) to
16 fractions to reduce sample complexity. After reversed-phase
desalting (C18 tips, Pierce), the samples were re-constituted
in water with 0.1% formic acid, then stored at −20◦C until
LC/MS/MS analysis. Western blotting procedures as described
previously (Maudsley et al., 2007; Martin et al., 2009a), were
performed using the same protein lysates employed for iTRAQ
labeling. Antibodies used were as follows: rabbit anti-BDNF
[(brain-derived neurotrophic factor) Santa Cruz Biotechnology,
Santa Cruz CA], rabbit antiphosphorylated TrkB and TrkB, rabbit
anti-phosphorylated Akt and Akt, rabbit antiphosphorylated
synapsin 1 and synapsin 1, rabbit anti-spinophilin, rabbit
anti-PSD95 and rabbit anti-synaptophysin (Cell signaling
technology, Inc., Danvers, MA), mouse anti-NeuN (EMD
Millipore Corporation, Billerica, MA) and mouse anti-beta actin
(Sigma-Aldrich, St. Louis, MO). Results were quantified and
statistical analysis was performed using an unpaired student
t-test. p < 0.05 was considered statistically significant.
LC/MS/MS ANALYSIS
Samples were analyzed using an Eksigent NanoLC Ultra 2D
(Dublin, CA) and Thermo Fisher Scientific LTQ Orbitrap XL
(San Jose, CA). In brief, peptides were first loaded onto a trap
cartridge (Agilent), then eluted onto a reversed phase PicoFrit
column (New Objective, Woburn, MA) using a linear 120min
gradient of acetonitrile (2–62%) containing 0.1% formic acid
at 250 nL/min flowrate. The eluted peptides were sprayed into
the LTQ Orbitrap XL. The data-dependent acquisition mode was
enabled, and each FTMS MS1 scan (60,000 resolution) was fol-
lowed by 6 MS2 scans (alternating CID at unit resolution and
HCD at 7500 resolution on 3 precursor ions). The spray voltage
and ion transfer tube temperature were set at 1.8 kV and 180◦C,
respectively.
DATABASE SEARCH AND iTRAQ QUANTIFICATION
Proteome Discoverer 1.2 (Thermo Fisher Scientific) was used
for protein identification and iTRAQ quantification using
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FIGURE 4 | Quantitative proteomic and bioinformatics analysis of BTBR
CNS tissues. Log2transformed iTRAQ ratio data (BTBR:WT) snake plot of the
proteins identified in the cortex (A) and hippocampus (B) are depicted.
Upregulated proteins are highlighted in red, while downregulated proteins are
highlighted in green. Three proteins identified by iTRAQ were validated via
western blot and results correlated to the iTRAQ results (C, D). Data are
expressed as means ± s.e.m. Asterisks represent p-values as shown:
∗p < 0.05. Statistical significance was measured using a Student’s t-test.
Sequest algorithms. The following criteria were followed:
SwissProt mouse database; enzyme: trypsin; miscleavages: 2;
static modifications: methylthio (+45.988Da on C), iTRAQ8plex
(+304.205Da on N-terminus and K); dynamic modifications:
oxidation (+15.995Da on M), deamidation (+0.984Da on N
and Q); peptide tolerance as 25 ppm; MS2 tolerance as 0.8Da.
Peptides reported via all search engines were accepted only if they
met the false discovery rate of 5%. For iTRAQ quantification, the
reporter ion intensities in MS2 spectra (m/z 113–121, integration
width tolerance 50mmu) were used to calculate the expression
ratios among the different conditions (Hippocampus and Cortex;
WT and BTBR).
BIOINFORMATICS ANALYSIS
Functional annotational clustering of our proteomic data, i.e.,
gene ontology (GO), KEGG (Kyoto Encyclopedia of Genes and
Genomes) pathway analysis was performed using WebGestalt
(http://bioinfo.vanderbilt.edu/webgestalt/, 3/2014) as previously
described (Chadwick et al., 2010a, 2011). In addition Ingenuity
Pathway Analysis (http://Ingenuity.com, 3/2014) was employed
for Canonical Signaling Pathway enrichment investigations. In
brief, GO analysis allows for broad clustering of genes into
functional groups, while KEGG pathways analysis allows for
more specific clustering into signaling pathways (Maudsley
et al., 2011). Inclusion criteria were set as follows: path-
way groups needed to meet a minimum population of two
genes from the input experimental set, and also needed to
possess a probability significance of enrichment compared to
a control background dataset of less than p < 0.05 (hyper-
geometric test of significance). In addition, Venn diagrams
were also constructed to identify common and uniquely
altered genes between hippocampus and cortex, using VennPlex
(Cai et al., 2013), as described previously (Martin et al.,
2009b).
TEXTROUS! LATENT SEMANTIC ANALYSIS-BASED INVESTIGATION
Textrous! latent semantic analysis was performed as described
previously (Chen et al., 2013). In brief, corresponding gene sym-
bols were uploaded into Textrous! (http://textrous.irp.nia.nih.
gov/, 3/2014) and then the relevant output indices, i.e., Cosine
Similarity, Z-score and p-value were extracted. In addition to
the direct list-based semantic output both the Collective pro-
cessing mode (generating hierarchical word-clouds), as well the
Individual processing mode (generating symbol-word heatmaps)
were applied to provide more nuanced informatic appreciation of
the specific input datasets.
STATISTICAL ANALYSIS
All statistical analyses were conducted using a Student’s t-test
(two-tailed with equal variances: GraphPad Prism, version 5.02).
p < 0.05 was considered statistically significant throughout the
study. Error bars represent 95% confidence interval. All data
represent means ± s.e.m. (standard error of mean). ∗p < 0.05;
∗∗p < 0.01; ∗∗∗p < 0.001.
Frontiers in Aging Neuroscience www.frontiersin.org September 2014 | Volume 6 | Article 225 | 6
Jasien et al. Aging and autism spectrum disorder
Table 1 | GO term analysis for cortical protein alterations observed in aged BTBR compared to WT control.
GO group GO term GO ID C O E R P H
Biological process Endoplasmic reticulum tubular network organization 71786 4 2 0.02 126.12 0.0047 293.595
Biological process Early endosome to late endosome transport 45022 21 3 0.08 36.03 0.0041 86.0114
Biological process Vesicle-mediated transport 16192 909 14 3.6 3.88 0.0018 10.64954
Biological process Secretion by cell 32940 693 11 2.75 4 0.0041 9.548865
Biological process Secretion 46903 795 12 3.15 3.81 0.0037 9.265151
Biological process Transmission of nerve impulse 19226 735 11 2.91 3.78 0.0047 8.79947
Biological process Neurological system process 50877 1237 16 4.9 3.26 0.002 8.798642
Biological process System process 3008 1695 19 6.72 2.83 0.002 7.638085
Biological process Multicellular organismal signaling 35637 751 11 2.98 3.69 0.0087 7.603174
Biological process Transport 6810 3338 30 13.23 2.27 0.0006 7.313597
Biological process Establishment of localization 51234 3392 30 13.45 2.23 0.0006 7.184723
Biological process Establishment of localization in cell 51649 1756 19 6.96 2.73 0.0027 7.012377
Biological process Cellular localization 51641 1977 20 7.84 2.55 0.0035 6.262626
Biological process Localization 51179 4167 31 16.52 1.88 0.0037 4.571781
Cellular component Chaperonin-containing T-complex 5832 7 2 0.03 78.59 0.0039 189.3182
Cellular component Pericentriolar material 242 12 2 0.04 45.84 0.0076 97.1435
Cellular component Clathrin-sculpted vesicle 60198 12 2 0.04 45.84 0.0076 97.1435
Cellular component Clathrin-coated vesicle membrane 30665 110 5 0.4 12.5 0.0011 36.98259
Cellular component Filopodium 30175 55 3 0.2 15 0.0076 31.7878
Cellular component Coated pit 5905 57 3 0.21 14.48 0.0082 30.20798
Cellular component Coated vesicle membrane 30662 150 5 0.55 9.17 0.0032 22.87777
Cellular component Lamellipodium 30027 121 4 0.44 9.09 0.0076 19.2634
Cellular component Ruffle 1726 123 4 0.45 8.94 0.0076 18.94553
Cellular component Neuron projection 43005 651 12 2.37 5.07 0.0002 18.75378
Cellular component Cell leading edge 31252 257 6 0.93 6.42 0.0039 15.46537
Cellular component Clathrin-coated vesicle 30136 207 5 0.75 6.64 0.0076 14.0714
Cellular component Cell projection 42995 1230 16 4.47 3.58 0.0002 13.24231
Cellular component Mitochondrion 5739 1525 18 5.54 3.25 0.0002 12.02165
Cellular component Cytoplasmic part 44444 6772 44 24.62 1.79 7.70E-05 7.363182
Cellular component Microtubule cytoskeleton 15630 863 10 3.14 3.19 0.0076 6.760205
Cellular component Cytoskeleton 5856 1790 15 6.51 2.3 0.0093 4.672489
Cellular component Cytoplasm 5737 9130 49 33.19 1.48 0.0007 4.669255
Cellular component Cytosol 5829 2372 18 8.62 2.09 0.0093 4.245871
Cellular component Intracellular 5622 12564 58 45.68 1.27 0.0012 3.70944
Cellular component Intracellular part 44424 12237 55 44.49 1.24 0.0082 2.586871
GO term annotation of the cortical proteins possessing BTBR:WT iTRAQ expression ratios <1.2 or <0.8 were created using WebGestalt. Each GO term group
significantly populated (p < 0.05) by at least two independent proteins are depicted. For each GO Term group the specific GO term ID, number of total proteins in
the curated GO term cluster (C), the number of observed experimental proteins in the GO term group (O), the expected number of proteins in the group based on
whole-genome background frequency (E), the GO term group enrichment factor (R), the GO term enrichment probability (P) and the hybrid score (R * −log10 P) are
indicated (H).
RESULTS
ASD-LIKE BEHAVIORAL PHENOTYPE PERSISTS IN AGED BTBR MICE
Commensurate with an extant ASD phenotype aged BTBR mice
demonstrated no sociability preference between an object or
another mouse, while WT controls spent significantly more time
with another mouse compared to an object (Figure 1A). Relative
percentage of time spent with either the mouse or the object
was used to calculate a social discrimination index [DI: (novel
time/total time-same time/total time) × 100] (Figure 2B). WT
and BTBR mice performed similarly in the novel object prefer-
ence test of learning and memory, with both groups spending
significantly more time with a novel object compared to a familiar
object (Figures 1C,D). Both WT and BTBR mice significantly
preferred to explore the peripheral areas of the chamber over
the center of the chamber, though the BTBR mice did show a
significantly higher preference for the periphery over the center
(Figure 1E). No significant differences in total distance trav-
eled (Figure 1F) or number of ambulatory episodes (Figure 1G)
were found. BTBR mice however demonstrated significantly less
jumping activity compared to WT (Figure 1H). In light-dark
exploration tests BTBR mice spent significantly more time in the
dark chamber compared to the lighted chamber, while WT con-
trol mice show no statistical difference in preference for either
chamber (Figure 1I). In the elevated plus maze test of anxiety,
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Table 2 | GO term analysis for hippocampal protein alterations observed in aged BTBR compared to WT controls.
GO Class GO Term GO ID C E O R P H
Biological process Neurotransmitter secretion 7269 99 15 1.25 11.98 4.40E–10 112.0914
Biological process Synaptic vesicle endocytosis 48488 22 6 0.28 21.57 8.46E–06 109.4166
Biological process Regulation of neuronal synaptic
plasticity
48168 47 9 0.59 15.14 4.14E–07 96.63861
Biological process Synaptic vesicle transport 48489 68 11 0.86 12.79 5.71E–08 92.64262
Biological process Regulation of synaptic plasticity 48167 96 13 1.21 10.71 1.68E–08 83.26694
Biological process Neurotransmitter transport 6836 133 15 1.68 8.92 1.21E–08 70.62155
Biological process Synaptic transmission 7268 651 41 8.23 4.98 8.14E–15 70.16509
Biological process Regulation of neurotransmitter levels 1505 137 15 1.73 8.66 1.54E–08 67.65607
Biological process Regulation of synaptic transmission 50804 186 18 2.35 7.65 3.76E–09 64.44981
Biological process Regulation of neurological system
process
31644 217 19 2.74 6.92 5.27E–09 57.28507
Biological process Regulation of transmission of nerve
impulse
51969 204 18 2.58 6.98 1.08E–08 55.6067
Biological process Transmission of nerve impulse 19226 735 41 9.29 4.41 2.94E–13 55.26459
Biological process Multicellular organismal signaling 35637 751 41 9.5 4.32 4.13E–13 53.4991
Biological process Respiratory electron transport chain 22904 110 12 1.39 8.63 8.22E–07 52.51466
Biological process Signal release 23061 344 23 4.35 5.29 8.37E–09 42.72878
Biological process Generation of a signal involved in
cell-cell signaling
3001 344 23 4.35 5.29 8.37E–09 42.72878
Biological process Cellular respiration 45333 159 14 2.01 6.96 8.22E–07 42.35249
Biological process Energy derivation by oxidation of
organic compounds
15980 329 22 4.16 5.29 1.54E–08 41.32802
Biological process Cell-cell signaling 7267 1099 48 13.9 3.45 3.98E–12 39.3304
Biological process Generation of precursor metabolites
and energy
6091 451 26 5.7 4.56 1.07E–08 36.34601
Biological process Neurological system process 50877 1237 44 15.64 2.81 1.54E–08 21.95307
Biological process Small molecule metabolic process 44281 2515 71 31.8 2.23 1.02E–09 20.05082
Biological process Cell morphogenesis involved in
neuron differentiation
48667 575 25 7.27 3.44 3.07E–06 18.96424
Biological process Regulation of biological quality 65008 2511 70 31.75 2.2 2.49E–09 18.92836
Biological process Neuron projection morphogenesis 48812 583 25 7.37 3.39 3.70E–06 18.4138
Biological process Neuron development 48666 798 31 10.09 3.07 1.11E–06 18.28086
Biological process Regulation of system process 44057 455 21 5.75 3.65 1.05E–05 18.17266
Biological process Secretion by cell 32940 693 28 8.76 3.2 2.39E–06 17.98913
Biological process Axonogenesis 7409 526 23 6.65 3.46 7.81E–06 17.67143
Biological process Neuron projection development 31175 704 28 8.9 3.15 3.07E–06 17.36551
Biological process Secretion 46903 795 30 10.05 2.98 3.07E–06 16.42833
Biological process Neuron differentiation 30182 990 34 12.52 2.72 3.46E–06 14.85371
Biological process Nervous system development 7399 1724 50 21.8 2.29 6.25E–07 14.20743
Biological process Establishment of localization in cell 51649 1756 50 22.21 2.25 1.01E–06 13.49028
Biological process Generation of neurons 48699 1073 35 13.57 2.58 6.71E–06 13.34706
Biological process Cellular localization 51641 1977 53 25 2.12 2.31E–06 11.94914
Biological process Establishment of localization 51234 3392 74 42.89 1.73 7.81E–06 8.835714
Biological process Transport 6810 3338 73 42.21 1.73 8.58E–06 8.765067
Biological process SinglE–multicellular organism process 44707 5612 106 70.97 1.49 4.87E–06 7.915582
Biological process Multicellular organismal process 32501 5644 106 71.37 1.49 6.63E–06 7.715945
Molecular function Malate dehydrogenase
(oxaloacetate-decarboxylating)
(NADP+) activity
4473 2 2 0.02 81.3 0.0023 214.4915
Molecular function Malate dehydrogenase
(oxaloacetate-decarboxylating) activity
16619 3 2 0.04 54.2 0.0039 130.5643
(Continued)
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Table 2 | Continued
GO Class GO Term GO ID C E O R P H
Molecular function Thioredoxin peroxidase activity 8379 3 2 0.04 54.2 0.0039 130.5643
Molecular function Malic enzyme activity 4470 4 2 0.05 40.65 0.0063 89.45681
Molecular function Hydrolase activity, acting on
carbon-nitrogen (but not peptide)
bonds, in cyclic amides
16812 10 3 0.12 24.39 0.0023 64.34746
Molecular function NAD binding 51287 49 7 0.6 11.61 0.0001 46.44
Molecular function Calmodulin-dependent protein kinase
activity
4683 21 4 0.26 15.49 0.0017 42.90035
Molecular function Proline-rich region binding 70064 15 3 0.18 16.26 0.0062 35.89571
Molecular function Syntaxin binding 19905 38 5 0.47 10.7 0.0017 29.6342
Molecular function NADH dehydrogenase (ubiquinone)
activity
8137 44 5 0.54 9.24 0.0023 24.37763
Molecular function NADH dehydrogenase (quinone)
activity
50136 44 5 0.54 9.24 0.0023 24.37763
Molecular function NADH dehydrogenase activity 3954 44 5 0.54 9.24 0.0023 24.37763
Molecular function SNARE binding 149 45 5 0.55 9.03 0.0023 23.8236
Molecular function Cofactor binding 48037 262 15 3.22 4.65 7.65E–05 19.14097
Molecular function Actin filament binding 51015 72 6 0.89 6.77 0.0033 16.79966
Molecular function Coenzyme binding 50662 186 11 2.29 4.81 0.0005 15.87795
Molecular function Oxidoreductase activity, acting on
NADH or NADPH, quinone or similar
compound as acceptor
16655 58 5 0.71 7.01 0.0062 15.47533
Molecular function Calmodulin binding 5516 164 10 2.02 4.96 0.0008 15.36067
Molecular function Hydrogen ion transmembrane
transporter activity
15078 101 7 1.24 5.63 0.0023 14.85347
Molecular function Cytoskeletal protein binding 8092 638 25 7.85 3.19 3.90E–05 14.0645
Molecular function Oxidoreductase activity 16491 711 24 8.75 2.74 0.0003 9.652688
Molecular function Actin binding 3779 356 14 4.38 3.2 0.0017 8.862563
Molecular function GTPase activity 3924 231 10 2.84 3.52 0.0057 7.899321
Molecular function Identical protein binding 42802 863 25 10.62 2.36 0.0012 6.893132
Molecular function Anion binding 43168 2402 54 29.55 1.83 0.0002 6.769115
Molecular function Small molecule binding 36094 2630 58 32.35 1.79 0.0002 6.621156
Molecular function Protein binding 5515 7337 126 90.25 1.4 2.47E–05 6.450224
Molecular function Nucleoside phosphate binding 1901265 2437 53 29.98 1.77 0.0005 5.842823
Molecular function Nucleotide binding 166 2436 52 29.96 1.74 0.0007 5.489529
Molecular function Nucleoside-triphosphatase activity 17111 760 21 9.35 2.25 0.0039 5.420105
Molecular function Pyrophosphatase activity 16462 794 21 9.77 2.15 0.0063 4.731418
Molecular function Hydrolase activity, acting on acid
anhydrides, in phosphorus-containing
anhydrides
16818 797 21 9.8 2.14 0.0063 4.709411
Molecular function Catalytic activity 3824 5371 94 66.07 1.42 0.0005 4.687463
Molecular function Hydrolase activity, acting on acid
anhydrides
16817 802 21 9.86 2.13 0.0063 4.687405
Molecular function Purine ribonucleoside triphosphate
binding
35639 1829 38 22.5 1.69 0.0063 3.719114
Molecular function Purine nucleoside binding 1883 1841 38 22.65 1.68 0.0063 3.697108
Molecular function Purine ribonucleoside binding 32550 1838 38 22.61 1.68 0.0063 3.697108
Molecular function Ribonucleoside binding 32549 1842 38 22.66 1.68 0.0063 3.697108
Molecular function Nucleoside binding 1882 1852 38 22.78 1.67 0.0068 3.61971
Molecular function Purine ribonucleotide binding 32555 1864 38 22.93 1.66 0.0073 3.546884
Cellular component Synapse 45202 489 28 5.45 5.14 3.35E–11 53.84127
Cellular component Mitochondrial respiratory chain 5746 69 8 0.77 10.41 6.79E–06 53.80024
(Continued)
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Table 2 | Continued
GO Class GO Term GO ID C E O R P H
Cellular component Neuron projection 43005 651 33 7.25 4.55 1.02E–11 50.01087
Cellular component Synaptic vesicle 8021 105 10 1.17 8.55 2.14E–06 48.47496
Cellular component Axon 30424 286 19 3.19 5.96 8.47E–09 48.10981
cellular component Respiratory chain 70469 76 8 0.85 9.45 1.32E–05 46.11058
Cellular component Clathrin-coated vesicle membrane 30665 110 10 1.23 8.16 3.21E–06 44.82692
Cellular component Vesicle membrane 12506 355 21 3.96 5.31 8.47E–09 42.86294
Cellular component Cytoplasmic vesicle membrane 30659 342 20 3.81 5.25 2.52E–08 39.89265
Cellular component Cytoplasm 5737 9130 170 101.72 1.67 1.52E–24 39.77632
Cellular component Cytoplasmic part 44444 6772 143 75.45 1.9 1.86E–21 39.38793
Cellular component Clathrin-coated vesicle 30136 207 14 2.31 6.07 7.60E–07 37.14346
Cellular component Cell projection 42995 1230 45 13.7 3.28 2.51E–11 34.76907
Cellular component Coated vesicle membrane 30662 150 11 1.67 6.58 6.79E–06 34.0063
Cellular component Cytoplasmic vesicle part 44433 401 21 4.47 4.7 6.16E–08 33.88897
Cellular component Cytosol 5829 2372 69 26.43 2.61 4.11E–13 32.32787
Cellular component Coated vesicle 30135 254 15 2.83 5.3 1.44E–06 30.96068
Cellular component Mitochondrion 5739 1525 48 16.99 2.83 5.17E–10 26.28082
Cellular component Synapse part 44456 370 18 4.12 4.37 1.46E–06 25.50178
Cellular component Membrane-bounded vesicle 31988 883 32 9.84 3.25 4.82E–08 23.7801
Cellular component Mitochondrial inner membrane 5743 354 17 3.94 4.31 3.58E–06 23.47276
Cellular component Cytoplasmic membrane-bounded
vesicle
16023 862 31 9.6 3.23 8.13E–08 22.90041
Cellular component Mitochondrial part 44429 744 27 8.29 3.26 5.82E–07 20.32635
Cellular component Organelle inner membrane 19866 384 17 4.28 3.97 1.01E–05 19.83284
Cellular component Vesicle 31982 970 32 10.81 2.96 3.20E–07 19.22476
Cellular component Cytoplasmic vesicle 31410 928 31 10.34 3 3.93E–07 19.21682
Cellular component Intracellular part 44424 12237 179 136.34 1.31 2.42E–13 16.5272
Cellular component Intracellular 5622 12564 180 139.98 1.29 1.32E–12 15.32446
Cellular component Organelle membrane 31090 2373 57 26.44 2.16 8.13E–08 15.3142
Cellular component Intracellular organelle part 44446 6725 120 74.93 1.6 5.80E–10 14.77852
Cellular component Organelle part 44422 6812 120 75.9 1.58 1.42E–09 13.97938
Cellular component Cytoskeleton 5856 1790 45 19.94 2.26 1.06E–06 13.50281
Cellular component Protein complex 43234 3278 70 36.52 1.92 9.89E–08 13.44922
Cellular component Cell part 44464 14643 189 163.15 1.16 1.90E–10 11.27665
Cellular component Cell 5623 14644 189 163.16 1.16 1.90E–10 11.27665
Cellular component Macromolecular complex 32991 3864 76 43.05 1.77 5.44E–07 11.08799
Cellular component Intracellular organelle 43229 10636 155 118.5 1.31 8.09E–08 9.290587
Cellular component Organelle 43226 10651 155 118.67 1.31 8.13E–08 9.287781
Cellular component Intracellular membrane-bounded
organelle
43231 9587 138 106.82 1.29 1.32E–05 6.29446
Cellular component Membrane-bounded organelle 43227 9598 138 106.94 1.29 1.36E–05 6.277735
GO term annotation of the cortical proteins possessing BTBR:WT iTRAQ expression ratios <1.2 or <0.8 were created using WebGestalt. Each GO term group
significantly populated (p<0.05) by at least two independent proteins are depicted. For each GO Term group the specific GO term ID, number of total proteins in
the curated GO term cluster (C), the number of observed experimental proteins in the GO term group (O), the expected number of proteins in the group based on
whole-genome background frequency (E), the GO term group enrichment factor (R), the GO term enrichment probability (P) and the hybrid score (R * −log10 P) are
indicated (H).
both WT and BTBR mice significantly preferred closed arms
to open arms (Figure 1J). Motor coordination, assessed using a
Rotarod test was similar in both groups (Figure 1K).
ALTERED PROTEIN EXPRESSION IN CNS OF AGED BTBR MICE
Cortical and hippocampal western blotting of proteins, selected
for their ability to indicate alterations of neurosynaptic activity,
was employed to detect potential expression differences between
aged WT and BTBR mice. Our panel of neurosynaptic factors
analyzed in cortical tissue is indicated in Figure 2A. No signifi-
cant difference betweenWT and BTBR pro-BDNF (brain-derived
neurotrophic factor) levels was detected (Figure 2B), whereas a
significant decreased in BTBR mature BDNF was observed com-
pared toWT (Figure 2C). Levels of phosphorylated TrkB receptor
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FIGURE 5 | Signaling pathway analysis of cortical and
hippocampal proteins differentially regulated BTBR and WT.
Cortical and hippocampal proteins exhibiting differential regulation
between BTBR and control mice were analyzed for potential
functional pathway interactions using KEGG (A-cortex,
B-hippocampus) and Ingenuity Canonical Signaling pathway analysis
(C-cortex, D-hippocampus). For (A,B), the top 10 most
significantly-populated (calculated with Hybrid scores: enrichment
factor (R) ∗ (−log10 enrichment probability, P) neuronally-specific
KEGG or Canonical signaling pathways are shown.
were similar in WT and BTBR cortex (Figure 2D) while the total
TrkB expression was significantly lower in BTBR mice compared
to WT (Figure 2E). No significant differences in Akt1 expres-
sion was noted in the BTBR model compared to WT (Figure 2F).
Levels of phosphorylated synapsin 1 (Figure 2G), but not total
synapsin 1 (Figure 2H) were significantly elevated in BTBR mice
compared to WT. Expression of both synaptophysin (Figure 2I)
and PSD95 (Figure 2J) was not affected in BTBR mice, while
both spinophilin (Figure 2K) and NeuN (Figure 2L) levels were
significantly elevated in BTBR mice compared to WT.
In the hippocampus we again found no significant differences
in the levels of pro-BDNF between BTBR and WT (Figure 3B)
that was coincident with a significant reduction in extant
BDNF levels (Figure 3C). Phosphorylated TrkB expression was
unchanged in BTBR mice compared to WT (Figure 3D), while
there was a trend, similar to that in the cortex, to reductions of
total TrkB receptor expression in the BTBR mice (Figure 3E). As
with the cortex no significant alterations in Akt1 were observed
(Figure 3F). Significant potentiation of both phosphorylated
(Figure 3G) and non-phosphorylated synapsin 1 (Figure 3H)
expression levels was seen in the BTBR hippocampus. In
accordance with the cortical data we found no significant
BTBR-induced changes in the hippocampal expression of synap-
tophysin (Figure 3I) or PSD95 (Figure 3J). Levels of both
spinophilin (Figure 3K) and NeuN (Figure 3L) were again sig-
nificantly potentiated in the BTBR mice, mirroring our previous
cortical data.
SYSTEMIC ANALYSIS OF BTBR CENTRAL NERVOUS PROTEIN
EXPRESSION
To gain an unbiased appreciation of the multiple tissue pro-
tein expression pattern changes generated in the BTBR mice
compare to WT we applied quantitative isobaric mass-tag label-
ing (iTRAQ) to cortical and hippocampal tissue extracts. In the
cortex we identified and generated relative expression profiles
for 674 proteins (Figure 4A: Table S1), while in the hippocam-
pus 656 proteins were identified and quantified in BTBR mice
(Figure 4B: Table S2). Log2-transformed iTRAQ expression ratios
were employed to generate snake plot graphs of individual pro-
teins. To initially validate some of the iTRAQ data we chose three
random proteins, Rab3A, CaMKIID and Cplx1 and found that at
the western level of detection our results were comparable to our
iTRAQ expression ratio data (Figures 4C,D).
GENE ONTOLOGY BIOINFORMATIC ANALYSIS OF BTBR-SPECIFIC
ALTERED PROTEINS
Using a standard arbitrary cut-off of >1.2 (elevated in BTBR
vs. WT) or <0.8 (reduced in BTBR vs. WT) for the iTRAQ
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Table 3 | KEGG Pathway analysis for cortical proteins altered in BTBR mice compared to WT controls.
KEGG pathway C E O R P H
Glutathione metabolism 50 2 0.07 27.38 0.0188 47.25356
MTOR signaling pathway 52 2 0.08 26.33 0.0188 45.44142
Arginine and proline metabolism 54 2 0.08 25.35 0.0188 43.7501
Shigellosis 61 2 0.09 22.44 0.0188 38.7279
Renal cell carcinoma 70 2 0.1 19.56 0.0188 33.75747
Chronic myeloid leukemia 73 2 0.11 18.75 0.0188 32.35954
Progesterone-mediated oocyte maturation 86 2 0.13 15.92 0.0188 27.47541
Gap junction 90 2 0.13 15.21 0.0188 26.25006
Melanogenesis 101 2 0.15 13.56 0.0192 23.27844
GnRH signaling pathway 101 2 0.15 13.56 0.0192 23.27844
Oocyte meiosis 112 2 0.16 12.22 0.0192 20.97806
Leukocyte transendothelial migration 116 2 0.17 11.8 0.0192 20.25705
Vascular smooth muscle contraction 116 2 0.17 11.8 0.0192 20.25705
Neurotrophin signaling pathway 127 2 0.19 10.78 0.0192 18.50601
Spliceosome 127 2 0.19 10.78 0.0192 18.50601
Tight junction 132 2 0.19 10.37 0.0192 17.80217
Hepatitis C 134 2 0.2 10.22 0.0192 17.54466
Natural killer cell mediated cytotoxicity 136 2 0.2 10.07 0.0192 17.28716
Insulin signaling pathway 138 2 0.2 9.92 0.0192 17.02965
Alzheimer’s disease 167 2 0.24 8.2 0.0261 12.98355
Chemokine signaling pathway 189 2 0.28 7.24 0.0313 10.89226
Metabolic pathways 1130 6 1.65 3.63 0.0188 6.264807
KEGG signaling pathway annotation of the cortical proteins possessing BTBR:WT iTRAQ expression ratios < 1.2 or < 0.8 was created using WebGestalt. Each KEGG
pathway significantly populated (p < 0.05) by at least two independent proteins are depicted. For each populated KEGG pathway the number of total proteins in the
curated KEGG pathway (C), the number of observed experimental proteins in the KEGG pathway (O), the expected number of proteins in the pathway based on
whole-genome background frequency (E), the KEGG pathway enrichment factor (R), the KEGG pathway enrichment probability (P) and the hybrid score (R * −log10
P) are indicated (H).
ratios for differentially expressed proteins between BTBR and
WT mice we investigated the functional clustering of the BTBR-
specific protein changes into Gene Ontology term groups.
Analysis of the differentially–regulated [elevated (<1.2) and
reduced (<0.8)] proteins in the BTBR cortex we found a
strong GO-biological process clustering of endoplasmic reticu-
lar, vesicular transport and neurotransmission related functions
(Table 1). No GO-molecular function annotation was achieved
with the cortical data however. With respect to GO-cellular
compartment analysis we found the differential BTBR proteins
were strongly associated with endocytic activity, neuronal out-
growth and architecture as well as mitochondrial metabolic
activity (Table 1). GO-biological process analysis of the dif-
ferential BTBR hippocampal protein set indicated a strong
bias toward neuronal synaptic secretion, neuronal plasticity,
metabolic activity and inter-cellular contact (Table 2). GO-
cellular compartment interrogation of the hippocampal dataset
revealed a strong bias for protein interactions in the synap-
tic cleft, clathrin-coated vesicles and mitochondrial-associated
metabolic areas (Table 2). GO-molecular function annotation
was evident with the hippocampal data and revealed the
presence of GO groups associated with malate metabolism,
redox activity, synaptic vesicle docking and structural modeling
(Table 2).
SIGNALING PATHWAY ANALYSIS OF DIFFERENTIALLY REGULATED
BTBR-SPECIFIC PROTEINS
While GO annotation indicates some degree of functional com-
monality between groups of proteins, associating multiple pro-
teins with classically-identified molecular signaling paradigms
provides additional functional information regarding the poten-
tial physiological ramifications of specific group of differentially-
regulated factors. We therefore performed both KEGG and
Ingenuity-base pathway analysis upon our cortical and hip-
pocampal BTBR protein sets. Inspecting the top ten highest scor-
ing KEGG pathways from cortical proteins (Figure 5A: Table 3)
a strong population of metabolic (Glutathione metabolism,
Insulin signaling pathway, Metabolic pathways), neurotransmis-
sion/degenerative (Neurotrophic signaling pathway, Alzheimer’s
disease) and ultrastructural (Gap junction, Tight junction,
Spliceosome) signaling pathways was evident. Applying the same
analysis to the hippocampus an intense population of signaling
systems linked to oxidative metabolism [Oxidative phosphoryla-
tion, Pyruvate metabolism, Citrate cycle (TCA cycle)] and cen-
tral neurodegeneration (Alzheimer’s disease, Huntington’s disease,
Parkinson’s disease, Long-term potentiation) was clear (Figure 5B:
Table 4). Extraction of potential physiological meaning from
complex data sets is best performed using multiple informatics
tools. Therefore, we also sought interpretation of the potential
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Table 4 | KEGG Pathway analysis for hippocampal proteins altered in BTBR mice compared to WT controls.
KEGG pathway C E O R P H
Oxidative phosphorylation 132 15 0.61 24.63 1.42E–15 365.6991
Alzheimer’s disease 167 17 0.77 22.06 1.03E–16 352.6768
Huntington’s disease 183 18 0.84 21.32 2.92E–17 352.518
Parkinson’s disease 130 12 0.6 20 1.88E–11 214.5168
Long–term potentiation 70 8 0.32 24.77 1.74E–08 192.2016
Gastric acid secretion 74 8 0.34 23.43 2.34E–08 178.7893
Collecting duct acid secretion 27 4 0.12 32.11 4.01E–05 141.183
Pyruvate metabolism 40 5 0.18 27.09 7.57E–06 138.7253
Metabolic pathways 1130 37 5.21 7.1 5.38E–19 129.7114
GnRH signaling pathway 101 8 0.47 17.17 2.19E–07 114.3446
Oocyte meiosis 112 8 0.52 15.48 4.04E–07 98.97322
Calcium signaling pathway 177 10 0.82 12.24 1.14E–07 84.98348
Vasopressin-regulated water reabsorption 44 4 0.2 19.7 0.0002 72.86971
Endocytosis 201 10 0.93 10.78 3.03E–07 70.27005
Citrate cycle (TCA cycle) 30 3 0.14 21.67 0.001 65.01
Butanoate metabolism 30 3 0.14 21.67 0.001 65.01
Propanoate metabolism 32 3 0.15 20.32 0.001 60.96
Alanine, aspartate and glutamate metabolism 32 3 0.15 20.32 0.001 60.96
Melanogenesis 101 6 0.47 12.87 4.15E–05 56.39572
Vibrio cholerae infection 54 4 0.25 16.05 0.0004 54.53694
Shigellosis 61 4 0.28 14.21 0.0007 44.83116
Wnt signaling pathway 150 7 0.69 10.11 4.01E–05 44.45221
Salivary secretion 89 5 0.41 12.18 0.0003 42.90866
Gap junction 90 5 0.42 12.04 0.0003 42.41546
Beta-Alanine metabolism 22 2 0.1 19.7 0.0071 42.33021
Glioma 65 4 0.3 13.34 0.0007 42.08639
Neurotrophin signaling pathway 127 6 0.59 10.24 0.0001 40.96
Valine, leucine and isoleucine degradation 44 3 0.2 14.78 0.0023 38.99366
Proteasome 44 3 0.2 14.78 0.0023 38.99366
Epithelial cell signaling in Helicobacter pylori infection 68 4 0.31 12.75 0.0009 38.83341
PPAR signaling pathway 70 4 0.32 12.38 0.0009 37.70648
Long-term depression 70 4 0.32 12.38 0.0009 37.70648
Bile secretion 71 4 0.33 12.21 0.0009 37.1887
Cardiac muscle contraction 77 4 0.36 11.26 0.0012 32.88842
Phosphatidylinositol signaling system 78 4 0.36 11.11 0.0012 32.4503
Pentose phosphate pathway 27 2 0.12 16.05 0.0103 31.89396
Amyotrophic lateral sclerosis (ALS) 53 3 0.24 12.27 0.0036 29.98417
ErbB signaling pathway 87 4 0.4 9.96 0.0016 27.84696
Inositol phosphate metabolism 57 3 0.26 11.41 0.0043 27.00212
Regulation of actin cytoskeleton 213 7 0.98 7.12 0.0003 25.0829
Glycolysis/Gluconeogenesis 65 3 0.3 10 0.0057 22.44125
Prion diseases 35 2 0.16 12.38 0.0158 22.30063
African trypanosomiasis 35 2 0.16 12.38 0.0158 22.30063
Pancreatic secretion 101 4 0.47 8.58 0.0026 22.17953
Adipocytokine signaling pathway 68 3 0.31 9.56 0.0064 20.97292
Bacterial invasion of epithelial cells 70 3 0.32 9.29 0.0066 20.25644
Renal cell carcinoma 70 3 0.32 9.29 0.0066 20.25644
Vascular smooth muscle contraction 116 4 0.54 7.47 0.0039 17.99475
Antigen processing and presentation 76 3 0.35 8.55 0.0081 17.88245
Purine metabolism 162 5 0.75 6.69 0.0023 17.65004
Protein processing in endoplasmic reticulum 165 5 0.76 6.57 0.0023 17.33345
Lysosome 121 4 0.56 7.16 0.0044 16.87288
(Continued)
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Table 4 | Continued
KEGG pathway C E O R P H
Spliceosome 127 4 0.59 6.83 0.005 15.71603
Chemokine signaling pathway 189 5 0.87 5.73 0.0036 14.00239
Rheumatoid arthritis 91 3 0.42 7.14 0.0127 13.53884
Fc gamma R-mediated phagocytosis 94 3 0.43 6.92 0.0136 12.91591
Taste transduction 52 2 0.24 8.34 0.0313 12.54716
MAPK signaling pathway 268 6 1.24 4.85 0.0032 12.10002
Arginine and proline metabolism 54 2 0.25 8.03 0.0325 11.94958
Pathogenic Escherichia coli infection 56 2 0.26 7.74 0.0342 11.34664
Chagas disease (American trypanosomiasis) 104 3 0.48 6.25 0.017 11.05969
Amoebiasis 106 3 0.49 6.13 0.0177 10.73992
Toxoplasmosis 132 3 0.61 4.93 0.0309 7.444505
Natural killer cell mediated cytotoxicity 136 3 0.63 4.78 0.0324 7.119595
Phagosome 153 3 0.71 4.25 0.0416 5.868853
KEGG signaling pathway annotation of the hippocampal proteins possessing BTBR:WT iTRAQ expression ratios < 1.2 or < 0.8 was created using WebGestalt. Each
KEGG pathway significantly populated (p < 0.05) by at least two independent proteins are depicted. For each populated KEGG pathway the number of total proteins
in the curated KEGG pathway (C), the number of observed experimental proteins in the KEGG pathway (O), the expected number of proteins in the pathway based
on whole-genome background frequency (E), the KEGG pathway enrichment factor (R), the KEGG pathway enrichment probability (P) and the hybrid score (R *
−log10 P) are indicated (H).
signaling pathways enriched in the BTBR tissues using canon-
ical signaling pathway analysis (Ingenuity). Canonical signaling
analysis of the cortex revealed a strong bias toward cytokine
signaling (Leptin signaling in obesity, JAK family kinases in
IL-6-type signaling), neurodegenerative disease related activity
(Amyloid processing, CDK5 signaling, CNTF signaling) and energy
metabolism (IGF-1 signaling) (Figure 5C: Table 5). Similar path-
way processing of hippocampal data again revealed a strong
prediction of metabolism-related activity (Oxidative phospho-
rylation, Mitochondrial dysfunction, G protein signaling medi-
ated by Tubby), neurodegenerative activity (Huntington’s disease
signaling) and interestingly, given the strong presentation of,
Melanocyte development and pigmentation signaling’ in the cor-
tex (Figure 5C), melatonin-related activity (Melatonin signaling)
(Figure 5D: Table 6).
BTBR-REGULATED COHERENT PROTEIN REGULATION PATTERNS
Along with our global analysis of protein set data from the two
tissues we also investigated the predicted functional nature of the
divergent expression polarity subsets of BTBR-specific proteins
uniquely regulated in either the cortex or hippocampus. Using
VennPlex (Figure 6A: Table 7) (Cai et al., 2013) we were able to
identify multiple groups of coherently-controlled proteins across
multiple CNS tissues. Using our previously developed informat-
ics application, Textrous!, we generated physiological predictions
extracted from multiple databases using latent semantic analysis
(Chen et al., 2013). Using the collective processing capacity of
Textrous!, which generates interactive hierarchical word-clouds,
we found that the tissue-unique up or down regulated sets of pro-
teins generated quite distinct functional signatures in the cortex
or hippocampus. For example, the specifically upregulated pro-
teins in the cortex were strongly focused into activity controlling
excitatory amino acid synaptic activity (Figure S1A: Table S3),
while the downregulated cortical only proteins demonstrated a
strong link to a reduction of protein kinase activity (Figure S1B:
Table S4). With respect to the hippocampus, the upregulated pro-
tein set appeared to be linked to increases in heat-shock factors
and synaptic pathophysiology (Figure S2A: Table S5), while the
downregulated hippocampal protein set suggested a reduction in
oligodendrocyte generation and CNS myelination (Figure S2B:
Table S6).
In addition to our global data set informatics interpreta-
tion we also sought to investigate the function of coherently-
regulated groups of BTBR-associated proteins observed across
multiple tissues. We therefore focused on the subset of proteins
(12 upregulated; 4 downregulated: Table 7) coherently altered
in a BTBR-specific manner in both the cortex and hippocam-
pus (Figure 6B). To explore the potential functional connec-
tion between these select proteins we applied our novel infor-
matic platform Textrous! (Chen et al., 2013). Textrous! allows
the extraction of functional data, using latent semantic anal-
ysis (LSA), from even the smallest of datasets. Textrous! is
a unique LSA tool as it possesses two forms of functional
data output, i.e., collective and individual processing. Collective
processing of the coherent BTBR protein set results in the
creation of a hierarchical word-cloud revealing a strong and
novel link between the BTBR ASD phenotype and N-WASP
(neuronal Wiskott–Aldrich Syndrome protein) mediated activ-
ity (Figure 6C: Table 8). In addition there was a second, less
strong demonstration of the importance of inherited genomic
activity in ASD phenotypes. The individual processing mode
in Textrous! also investigates the strongest individual protein-
term relationships within a specific protein subset (Figure 6D).
Again with this distinct analytical output we observed a strong
relationship between cytoskeletal remodeling activity (f-actin,
scaffolding, n-wasp, filopodia) and proteins such as Itsn1 (inter-
sectin 1), Ap3b2 (adaptor-related protein complex 3, beta
2 subunit), Dbnl (drebrinlike) and Ermn (Ermin, ERM-like
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Table 5 | Ingenuity Canonical Signaling Pathway analysis of proteins
differentially regulated in the cortex of aged BTBR compared to WT
controls.
Canonical pathways log(p-value) Ratio 10 × Hybrid
Leptin Signaling in Obesity 3.97E + 00 4.71E–02 1.86987
Role of JAK family kinases in
IL-6-type Cytokine Signaling
2.52E + 00 7.14E–02 1.79928
Amyloid Processing 3.20E + 00 4.92E–02 1.5744
Melanocyte Development
and Pigmentation Signaling
3.73E + 00 4.21E–02 1.57033
Gαi Signaling 3.16E + 00 2.96E–02 0.93536
Dopamine Receptor Signaling 2.70E + 00 3.12E–02 0.8424
CDK5 Signaling 2.52E + 00 3.09E–02 0.77868
α-Adrenergic Signaling 2.52E + 00 2.75E–02 0.693
IGF-1 Signaling 2.40E + 00 2.80E–02 0.672
CNTF Signaling 1.90E + 00 3.51E–02 0.6669
Neuropathic Pain Signaling In
Dorsal Horn Neurons
2.36E + 00 2.75E–02 0.649
G Beta Gamma Signaling 2.50E + 00 2.48E–02 0.62
IL-2 Signaling 1.88E + 00 3.28E–02 0.61664
Thrombopoietin Signaling 1.85E + 00 3.12E–02 0.5772
Renin-Angiotensin Signaling 2.26E + 00 2.38E–02 0.53788
Gαs Signaling 2.22E + 00 2.40E–02 0.5328
Role of JAK1 and JAK3 in γc
Cytokine Signaling
1.75E + 00 2.94E–02 0.5145
GM-CSF Signaling 1.74E + 00 2.94E–02 0.51156
Clathrin-mediated
Endocytosis Signaling
2.49E + 00 2.02E–02 0.50298
Regulation of Cellular
Mechanics by Calpain
Protease
1.82E + 00 2.74E–02 0.49868
CREB Signaling in Neurons 2.58E + 00 1.93E–02 0.49794
Glutamate Receptor Signaling 1.79E + 00 2.78E–02 0.49762
Synaptic Long Term
Potentiation
2.14E + 00 2.31E–02 0.49434
Antiproliferative Role of
Somatostatin Receptor 2
1.73E + 00 2.78E–02 0.48094
Agrin Interactions at
Neuromuscular Junction
1.68E + 00 2.86E–02 0.48048
JAK/Stat Signaling 1.69E + 00 2.82E–02 0.47658
Corticotropin Releasing
Hormone Signaling
2.21E + 00 2.07E–02 0.45747
Neurotrophin/TRK Signaling 1.68E + 00 2.63E–02 0.44184
P2Y Purigenic Receptor
Signaling Pathway
2.12E + 00 2.08E–02 0.44096
Renal Cell Carcinoma
Signaling
1.65E + 00 2.53E–02 0.41745
Insulin Receptor Signaling 2.03E + 00 2.01E–02 0.40803
Melatonin Signaling 1.65E + 00 2.47E–02 0.40755
FLT3 Signaling in
Hematopoietic Progenitor
Cells
1.60E + 00 2.53E–02 0.4048
GNRH Signaling 2.05E + 00 1.96E–02 0.4018
cAMP-mediated signaling 2.23E + 00 1.77E–02 0.39471
Ephrin B Signaling 1.61E + 00 2.44E–02 0.39284
Prolactin Signaling 1.62E + 00 2.38E–02 0.38556
BMP signaling pathway 1.59E + 00 2.33E–02 0.37047
(Continued)
Table 5 | Continued
Canonical pathways log(p-value) Ratio 10 × Hybrid
Relaxin Signaling 1.98E + 00 1.83E–02 0.36234
FGF Signaling 1.49E + 00 2.13E–02 0.31737
Gap Junction Signaling 1.83E + 00 1.66E–02 0.30378
Apoptosis Signaling 1.47E + 00 2.00E–02 0.294
Acute Phase Response
Signaling
1.74E + 00 1.66E–02 0.28884
G-Protein Coupled Receptor
Signaling
1.99E + 00 1.45E–02 0.28855
Mouse Embryonic Stem Cell
Pluripotency
1.41E + 00 2.02E–02 0.28482
Neuregulin Signaling 1.47E + 00 1.92E–02 0.28224
FAK Signaling 1.48E + 00 1.89E–02 0.27972
Chronic Myeloid Leukemia
Signaling
1.42E + 00 1.89E–02 0.26838
VEGF Signaling 1.43E + 00 1.83E–02 0.26169
IL-1 Signaling 1.42E + 00 1.83E–02 0.25986
Sertoli Cell-Sertoli Cell
Junction Signaling
1.69E + 00 1.52E–02 0.25688
PPARα/RXRα Activation 1.69E + 00 1.50E–02 0.2535
HGF Signaling 1.37E + 00 1.80E–02 0.2466
Mitochondrial Dysfunction 1.76E + 00 1.40E–02 0.2464
Ephrin Receptor Signaling 1.70E + 00 1.43E–02 0.2431
Role of NFAT in Cardiac
Hypertrophy
1.66E + 00 1.44E–02 0.23904
Calcium Signaling 1.67E + 00 1.38E–02 0.23046
Integrin Signaling 1.57E + 00 1.44E-02 0.22608
Leukocyte Extravasation
Signaling
1.56E + 00 1.43E-02 0.22308
Breast Cancer Regulation by
Stathmin1
1.59E + 00 1.40E–02 0.2226
Fc Epsilon RI Signaling 1.30E + 00 1.71E–02 0.2223
Nitric Oxide Signaling in the
Cardiovascular System
1.36E + 00 1.60E–02 0.2176
NGF Signaling 1.32E + 00 1.64E–02 0.21648
Axonal Guidance Signaling 1.86E + 00 1.03E–02 0.19158
Cardiac Hypertrophy
Signaling
1.42E + 00 1.20E–02 0.1704
Molecular Mechanisms of
Cancer
1.58E + 00 1.03E–02 0.16274
Colorectal Cancer Metastasis
Signaling
1.34E + 00 1.12E–02 0.15008
Protein Kinase A Signaling 1.43E + 00 9.78E–03 0.139854
Canonical signaling pathway annotation of the cortical proteins possessing
BTBR:WT iTRAQ expression ratios <1.2 or <0.8 was created using Ingenuity
Pathway Analysis. Each signaling pathway significantly populated (p < 0.05) by
at least two independent proteins are depicted. For each populated signaling
pathway the −log10 of the enrichment probability (p-value), the enrichment ratio
and the calculated hybrid score [10 * (enrichment ratio * −log10(p-value))] are
depicted.
protein) with the BTBR phenotype. Interestingly other tight
relationships between BTBR coherently-regulated factors were
found, e.g., myelin-associated activity [Lancl1 (LanC bacterial
lantibiotic synthetase component C)-like 1 and Ermn] and
inherited neuronal atrophy and impairment [Prrt2 (proline-rich
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Table 6 | Ingenuity Canonical Signaling Pathway analysis of proteins
differentially regulated in the hippocampus of aged BTBR compared
to WT controls.
Canonical pathways −log(p-value) Ratio 10 × Hybrid
Oxidative phosphorylation 1.27E + 01 1.25E–01 15.875
Mitochondrial dysfunction 1.33E + 01 8.37E–02 11.1321
GABA receptor signaling 5.19E + 00 1.07E–01 5.5533
Glutamate degradation III (via
4-aminobutyrate)
3.02E + 00 1.67E–01 5.0434
GM-CSF signaling 4.44E + 00 8.82E–02 3.91608
Huntington’s disease signaling 6.46E + 00 5.16E–02 3.33336
G protein signaling mediated
by Tubby
3.47E + 00 9.09E–02 3.15423
Melatonin signaling 4.18E + 00 7.41E–02 3.09738
RhoA signaling 4.52E + 00 6.25E–02 2.825
Lipid antigen presentation by
CD1
2.68E + 00 1.00E–01 2.68
Regulation of actin-based
motility by rho
3.77E + 00 6.52E–02 2.45804
Role of NFAT in cardiac
hypertrophy
4.87E + 00 4.78E–02 2.32786
CTLA4 Signaling in cytotoxic T
lymphocytes
3.63E + 00 6.25E–02 2.26875
TCA Cycle II (Eukaryotic) 2.90E + 00 7.50E–02 2.175
Breast cancer regulation by
stathmin1
4.65E + 00 4.67E–02 2.17155
Chemokine signaling 3.22E + 00 6.67E–02 2.14774
Synaptic long term
potentiation
3.72E + 00 5.38E–02 2.00136
Guanine and guanosine
salvage I
1.71E + 00 1.11E–01 1.8981
CREB signaling in neurons 4.21E + 00 4.35E–02 1.83135
β-alanine degradation I 1.71E + 00 1.00E–01 1.71
Axonal guidance signaling 5.19E + 00 3.29E–02 1.70751
GNRH signaling 3.51E + 00 4.58E–02 1.60758
Actin nucleation by
ARP-WASP complex
2.65E + 00 5.97E–02 1.58205
4-Aminobutyrate degradation I 1.53E + 00 1.00E–01 1.53
Superpathway of inositol
phosphate compounds
3.94E + 00 3.85E–02 1.5169
Creatine-phosphate
biosynthesis
1.32E + 00 1.11E–01 1.4652
Pyruvate fermentation to
lactate
1.32E + 00 1.11E–01 1.4652
D-myo-inositol-5-phosphate
metabolism
3.32E + 00 4.32E–02 1.43424
fMLP signaling in neutrophils 3.13E + 00 4.55E–02 1.42415
Methylglyoxal degradation I 1.53E + 00 9.09E–02 1.39077
Clathrin-mediated endocytosis
signaling
3.29E + 00 4.04E–02 1.32916
Ephrin receptor signaling 3.45E + 00 3.81E–02 1.31445
Protein kinase A signaling 3.95E + 00 3.18E–02 1.2561
Thrombin signaling 3.20E + 00 3.79E–02 1.2128
3-phosphoinositide
biosynthesis
3.10E + 00 3.87E–02 1.1997
(Continued)
Table 6 | Continued
Canonical pathways −log(p-value) Ratio 10 × Hybrid
D-myo-inositol
(1,4,5,6)-tetrakisphosphate
biosynthesis
2.86E + 00 4.17E–02 1.19262
D-myo-inositol
(3,4,5,6)-tetrakisphosphate
biosynthesis
2.86E + 00 4.17E–02 1.19262
Methylmalonyl pathway 1.41E + 00 8.33E–02 1.17453
Neuropathic pain signaling in
dorsal horn neurons
2.50E + 00 4.59E–02 1.1475
G beta gamma signaling 2.73E + 00 4.13E–02 1.12749
nNOS signaling in neurons 1.95E + 00 5.77E–02 1.12515
Signaling by rho family
GTPases
3.24E + 00 3.36E–02 1.08864
Arginine degradation I
(arginase pathway)
1.41E + 00 7.69E–02 1.08429
Ephrin B signaling 2.21E + 00 4.88E–02 1.07848
Purine nucleotides de novo
biosynthesis II
2.22E + 00 4.76E–02 1.05672
Leptin signaling in obesity 2.19E + 00 4.71E–02 1.03149
Semaphorin signaling in
neurons
1.83E + 00 5.56E–02 1.01748
Inosine-5’-phosphate
biosynthesis II
1.53E + 00 6.25E–02 0.95625
Actin cytoskeleton signaling 2.88E + 00 3.31E–02 0.95328
3-phosphoinositide
degradation
2.57E + 00 3.70E–02 0.9509
Rac signaling 2.43E + 00 3.91E–02 0.95013
iCOS-iCOSL signaling in T
helper cells
2.38E + 00 3.97E–02 0.94486
Dopamine receptor signaling 2.17E + 00 4.17E–02 0.90489
Molybdenum cofactor
biosynthesis
1.41E + 00 6.25E–02 0.88125
Aldosterone signaling in
epithelial cells
2.38E + 00 3.55E–02 0.8449
CD28 signaling in T helper
cells
2.23E + 00 3.68E–02 0.82064
B cell receptor signaling 2.30E + 00 3.43E–02 0.7889
2-oxobutanoate degradation I 1.32E + 00 5.88E–02 0.77616
PKCθ signaling in T
lymphocytes
2.23E + 00 3.47E–02 0.77381
Virus entry via endocytic
pathways
1.93E + 00 3.96E–02 0.76428
P2Y purigenic receptor
signaling pathway
2.14E + 00 3.47E–02 0.74258
D-myo-inositol
(1,4,5)-trisphosphate
biosynthesis
1.48E + 00 5.00E–02 0.74
Dopamine-DARPP32 feedback
in cAMP signaling
2.25E + 00 3.21E–02 0.72225
PI3K signaling in B
lymphocytes
2.05E + 00 3.50E–02 0.7175
α-Adrenergic signaling 1.95E + 00 3.67E–02 0.71565
Protein ubiquitination pathway 2.41E + 00 2.96E–02 0.71336
Gluconeogenesis I 1.67E + 00 4.26E–02 0.71142
(Continued)
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Table 6 | Continued
Canonical pathways −log(p-value) Ratio 10 × Hybrid
Glutamate receptor signaling 1.69E + 00 4.17E–02 0.70473
G-Protein coupled receptor
signaling
2.38E + 00 2.90E–02 0.6902
IL-1 signaling 1.87E + 00 3.67E–02 0.68629
Antiproliferative role of
somatostatin receptor 2
1.60E + 00 4.17E–02 0.6672
Remodeling of epithelial
adherens junctions
1.53E + 00 4.29E–02 0.65637
JAK/stat signaling 1.54E + 00 4.23E–02 0.65142
Glioma signaling 1.84E + 00 3.54E–02 0.65136
Role of NFAT in regulation of
the immune response
2.15E + 00 3.00E–02 0.645
Fatty acid β-oxidation I 1.45E + 00 4.44E–02 0.6438
RhoGDI signaling 2.11E + 00 2.97E–02 0.62667
Cardiac β-adrenergic signaling 1.96E + 00 3.16E–02 0.61936
Cardiac hypertrophy signaling 2.15E + 00 2.80E–02 0.602
Relaxin signaling 1.93E + 00 3.05E–02 0.58865
Renal cell carcinoma signaling 1.50E + 00 3.80E–02 0.57
Calcium signaling 2.05E + 00 2.76E–02 0.5658
Phospholipase C signaling 2.06E + 00 2.64E–02 0.54384
Gαq signaling 1.80E + 00 2.92E–02 0.5256
Gαs signaling 1.60E + 00 3.20E–02 0.512
Molecular mechanisms of
cancer
2.15E + 00 2.32E–02 0.4988
Role of tissue factor in cancer 1.61E + 00 3.08E–02 0.49588
Gap junction signaling 1.71E + 00 2.76E–02 0.47196
p70S6K signaling 1.51E + 00 3.03E-02 0.45753
Androgen signaling 1.60E + 00 2.76E–02 0.4416
Gαi signaling 1.48E + 00 2.96E–02 0.43808
cAMP-mediated signaling 1.65E + 00 2.65E–02 0.43725
PPARα/RXRα activation 1.51E + 00 2.50E–02 0.3775
Insulin receptor signaling 1.38E + 00 2.68E–02 0.36984
eNOS signaling 1.39E + 00 2.58E–02 0.35862
Glucocorticoid receptor
signaling
1.35E + 00 2.01E–02 0.27135
Canonical signaling pathway annotation of the hippocampal proteins possessing
BTBR:WT iTRAQ expression ratios < 1.2 or < 0.8 was created using Ingenuity
Pathway Analysis. Each signaling pathway significantly populated (p < 0.05) by
at least two independent proteins are depicted. For each populated signaling
pathway the −log10 of the enrichment probability (p-value), the enrichment ratio
and the calculated hybrid score [10 * (enrichment ratio * −log10(p-value))] are
depicted.
transmembrane protein 2) and Cep290 (centrosomal protein
290)] (Figure 6D).
DISCUSSION
In the present study we evaluated the behavior, synaptic protein
alterations and targeted proteomic signatures in the hippocam-
pus and cortex of 15 month old BTBR andWTmice to determine
whether the ASD-like phenotype of BTBR mice was resistant to
neuronal aging. Thus, we assessed both the behavioral phenotype
and proteomic profiles between aged ASD-like mice (abnormal
CNS) and aged wild type mice (with a relatively normal CNS).
We found that several neurosynaptic proteins were significantly
increased in both the hippocampus and cortex of the aged ASD-
like mice in comparison to the aged wild type. In particular,
the phosphorylated form of the pre-synaptic marker synapsin
1, and the post-synaptic marker spinophilin were increased in
both the aged BTBR hippocampus and cortex; PSD95 was sig-
nificantly elevated in aged BTBR hippocampus. Aged BTBR mice
still presented a behavioral phenotype typically observed in young
autistic mice, suggesting that the physiological actions underlying
the ASD-like condition of the BTBR mice is relatively resistant to
aging.
The maintenance of the ASD-phenotype into advanced age in
BTBR mice is intriguing because in the normal developing CNS
synapses are overproduced but then become pruned in response
to neuronal activity during post-natal development (Petit, 1988;
Cohen and Greenberg, 2008; Ebert and Greenberg, 2013). It is
proposed that autism is caused by dysregulation of the machin-
ery controlling synaptic messenger RNA translation leading to
increased synthesis of synaptic proteins and lack of synaptic prun-
ing, in turn inducing a hyperconnectivity and over-reinforcement
of neuronal circuits. In fact it is one of the hallmark character-
istics of ASD observed in the brains of both mouse models and
humans with ASD (Kelleher and Bear, 2008; Gkogkas et al., 2013).
Fragile X syndrome, for example which is the leading cause of
inherited intellectual disability and ASD (Bhakar et al., 2012), is
caused by mutations in FMR1 gene resulting in decreased expres-
sion of fragile X mental retardation protein (FMRP). This protein
modulates the rate of translational elongation of mRNAs that
encode synaptic proteins (Darnell et al., 2011). A decrease in
FMRP impairs regulation of synaptic protein expression (Bhakar
et al., 2012) and post-natal synapse elimination (Harlow et al.,
2010).
As increased synaptic marker expression is associated with
the autistic-like mouse phenotype it is not surprising that we
found that the BTBR T + tf/j mice maintained their reduced
social behavior into old age (Figure 1). This is consistent with
the limited human literature that found that social impairments
in individuals with ASD persist into adulthood (Ballaban-Gil
et al., 1996; Szatmari, 1998; Howlin and Moss, 2012). Although
increased synaptic markers have been found to be deleterious
for the developing CNS, it is possible that the increased synapses
and hyperconnected neuronal circuits be an effective advantage in
the aging process where typically nervous system connectivity is
degraded through accumulated damage. BDNF and TrkBmRNAs
are localized in dendritic spines, thus age-related spine den-
sity decreases in older individuals suggest a link between BDNF
and TrKB mRNA expression and impaired synaptic connections
with aging (Tapia-Arancibia et al., 2008). Indeed decreases in
both BDNF and TrkB expression have been documented in the
hippocampus and in the neocortex during physiological aging
(Phillips et al., 1991; Murray et al., 1994; Connor et al., 1997;
Ferrer et al., 1999; Quartu et al., 1999; Hock et al., 2000; Holsinger
et al., 2000; Fahnestock et al., 2002; Romanczyk et al., 2002;
Tapia-Arancibia et al., 2008; Zhao et al., 2010).
We found that levels of mature BDNF were significantly
decreased in the aged BTBR hippocampus and cortex compared
with the aged WT (Figures 2A, 3A), suggesting an accelerated
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FIGURE 6 | Identification of coherent regulatory protein signatures in
BTBR CNS tissues. Vennplex diagram analysis of the upregulated (BTBR:WT
iTRAQ ratio > 1.2) or downregulated (iTRAQ ratio < 0.8) proteins in both the
hippocampus and cortex are depicted (A). A small coherently-regulated
protein subset across both tissues was evident and comprised a focused
protein set strongly linked to human ASD-like conditions (B). Textrous!-based
collective processing interrogation of the coherently-regulated BTBR protein
set revealed, in the resultant hierarchical word-cloud, a strong potential role
of skeletal modeling activity in this protein set (C). This skeletal signaling
dependence of ASD was confirmed using the individual processing module
of Textrous! (D). In this heatmap output correlation strength between protein
and functional term is indicated by the intensity of the teal-colored blocks.
aging phenomena, but did not find a significant change in the
overall level of active TrkB receptor (Figures 2D, 3D), in the
BTBR mice. In addition, we also found that there was a non-
significant trend for the increase in the expression in both cortical
and hippocampal levels of Akt1, one of the most important
downstream targets of TrkB signaling. Thus, via a potentially
complex compensatory mechanism, the BTBR mice may have
increased their BDNF signaling efficiency and downstream signal
transduction capacity compared to WT mice.
Our findings of reduced BDNF in both the hippocampus and
cortex in old BTBRmice compared to oldWTmice despite seem-
ingly intact memory functioning may be related to this efficiency
potentiation of the BDNF-TrkB system in the BTBR mice. These
effects may be related to changes in endocytic proteins such as
Itsn1, Golga2 and Ap3b2 (Table 7) that may affect the signaling
dynamics of the TrkB receptor (Mattson et al., 2004). In addition
it is possible that the elevated levels of various synaptic mark-
ers served to protect the aging BTBR brain against age-related
declines in cognition often associated with decreased levels of
BDNF.
Given the complexity of the ASD, it is unlikely that BDNF
signaling and various neuronal cell markers are the only pro-
tein products altered in the presence of ASD; thus we performed
global quantitative iTRAQ proteomics, coupled to advanced
bioinformatics in order to gain a comprehensive, systems-level
understanding of potential changes in aged BTBRmice compared
toWT counterparts. With respect to current relevant literature we
discovered that many of these proteins differentially regulated in
the brain of the old BTBR mice demonstrated strong correlations
with those altered in humans with neurodevelopmental disabili-
ties (Table S7). Nearly twenty percent of the coherently-regulated
proteins across the hippocampus and cortex of aged BTBR mice
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also are strongly linked to human ASD phenotypes, suggest-
ing that future investigation of the remaining factors may prove
extremely fruitful for autism-related research (Figure 6B). With
respect to the highly-focused, coherently-regulated protein set
(Figure 6B: Table 7) Prrt2 was coherently altered in both the hip-
pocampus and cortex of aged BTBR mice compared to aged WT
(Table 7). Alterations in activity of Prrt2 have been found in the
frontal cortex of individuals with autism (Ji et al., 2012) and have
also been genetically-associated with ASD (Weber et al., 2013).
Vat1l was up-regulated in both the hippocampus and cortex of
the old BTBR mice.
We performed functional informatics data clustering to gain
a wider appreciation of the signaling phenotype present in aged
BTBR mice. Using GO term annotation it was evident in the
cortex that considerable alterations in ER (endoplasmic reticu-
lum), vesicular transport, cytoskeletal remodeling, and energy
generation were apparent (Figures 4E,F). The functional GO
term clustering of differentially expressed proteins in the BTBR
hippocampus also indicated a role of energy generation, neu-
rotransmitter release and synaptic activity but did not display
a robust skeletal remodeling component (Table 2). We also
employed KEGG and Ingenuity Canonical Signaling pathway
analysis for the differentially-regulated cortex and hippocam-
pal protein sets. At this higher level of functional interrogation
(compared to GO term clustering) we also observed a subtle
divergence in tissue behavior, i.e., cortical KEGG pathway anal-
ysis demonstrated a strong bias toward energy metabolic and
neurotrophic/neuroprotective mechanisms (Figure 5A) while the
hippocampus demonstrated a more degenerative phenotype
associated with metabolic instabilities and calcium management
factors (Figure 5B). Interestingly and to highlight the need for
multidimensional informatics analyses for physiological interpre-
tation, the canonical signaling pathway analysis of both tissue
datasets revealed additional processes that could affect the ASD
phenotype, i.e., the prominence of cytokine signaling activity in
the cortex and the identification of the potential role of melatonin
function in both CNS tissues (Figures 5C,D).
To further reinforce the importance of applying unbiased
informatics for the analysis of complex data associated with a
highly nuanced phenotype such as ASD we found that analysis
of different subgroups of the data yielded interesting, tissue-
specific insights into the effects of aging on ASD. Using our
novel Textrous! platform we were able to identify differential
tissue activity, i.e., enhanced glutamatergic cortical activity coin-
cident with attenuated kinase signaling (Figure S1). These cor-
tical changes occurred contemporaneously with an elevation of
hippocampal protein misfolding/aggregation coincident with an
attenuated CNS myelination and oligodendrocyte functional-
ity (Figure S2). Both of these hippocampal processes have been
recently associated with dysfunctional brain development (Mitew
et al., 2013).
When approaching complex issues such as ASD with a
systems-biology approach it is important tomaintain this concept
of multiple levels of protein interaction, function and hierarchi-
cal architecture, i.e., functions can be tissue specific, expression
polarity specific while also existing contemporaneously at a level
above tissue-or polarity-dependence. For example we found that
Table 7 | VennPlex Venn diagram analysis of up and downregulated
proteins across the cortex and hippocampus of BTBR mice compared
to WT controls.
Protein Cortex up Cortex down Hippo up Hippo down
PRRT2 1.951168338 2.381953722
DYNLL1 1.672920918 1.737545789
DBNL 1.626693344 1.24548243
AP3B2 1.581785753 1.789312776
VAT1L 1.391942674 1.401775589
WDR33 1.379833997 2.510567518
GOLGA2 1.292500223 1.60040989
LANCL1 1.279121599 1.320074872
ME3 1.270939623 1.62730561
ITSN1 1.269638936 1.774926636
CEP290 1.238621608 1.454207016
PCYOX1L 1.209317219 1.860882083
ERMN −1.243267187 −1.500264003
CSRP1 −1.365689412 −1.509867503
DBI −1.496288514 −2.056916039
NUCB1 −1.631205729 −3.561025937
EIF5A 1.517756095 −1.65673365
MMAA 1.391228352 −1.887879989
PTPN11 1.247745108 −3.093767449
ZXDB 1.214676409 −1.393599577
SLC17A7 1.204082729 −1.315805498
DPYSL4 1.195193712 −1.314442062
OAT −1.307905257 1.362629072
Ptcd 1.828557315
PCBP2 1.792502849
QDPR 1.7625157
SRSF4 1.533013648
ADCY2 1.511246891
NDUFS4 1.47998035
SLC9A3R1 1.473396618
LETM1 1.455678341
PRDX3 1.44243043
IDH2 1.441010435
EXOC5 1.41342868
HNRNPUL2 1.405691244
PTCD1 1.371753507
DDX5 1.365841661
PPP1R9B 1.346708939
DPP6 1.340020376
LAP3 1.303333413
KCNAB2 1.296085587
SLC12A5 1.252190507
HOOK3 1.250023514
COX5A 1.247002966
WDR1 1.244912709
GRM2 1.243617897
CAB39 1.2340405
RTN3 1.233971862
TF 1.233243832
FBXO41 1.231290747
RAB7A 1.226744118
RTN4 1.216638369
TCP1 1.215498024
(Continued)
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Table 7 | Continued
Protein Cortex up Cortex down Hippo up Hippo down
PRKAR2B 1.215235782
CCT3 1.20748828
PRDM5 1.198502382
COQ9 −1.24961385
CLDN11 −1.260614004
NCALD −1.266374541
F5 −1.269955566
EXOC6B −1.275380087
CTTN −1.287911813
VBP1 −1.361766656
PICALM −1.466374966
CAPNS1 −1.756445493
TOMM20 −1.819905488
MAPK3 −1.918813356
NUDC 1.732009523
RAP2B 1.726355193
KIF2A 1.663032474
SETDB1 1.648556725
ATP6V1D 1.640964877
SYNGR1 1.58532711
DPYSL3 1.582802831
NCAN 1.571585688
CTNND2 1.562506309
CNRIP1 1.554254382
UTP20 1.544855143
ME1 1.478800627
PFN1 1.477145399
PPME1 1.455765369
APP 1.455465641
LANCL2 1.455132031
GNAQ 1.453050806
ARPC5L 1.451224208
PRDX2 1.448929334
CYFIP1 1.432347642
HSPA2 1.431503207
SFPQ 1.427372534
TXLNG 1.42119969
GRB2 1.4157442
CPNE6 1.414165286
PDXP 1.410098436
GNB2 1.408516442
GLOD4 1.391614359
OXR1 1.380069445
VAMP2 1.373709575
HSPA1A 1.373028035
HSPA1B 1.373028035
PSD3 1.371411227
BSG 1.369172074
PFN2 1.368469072
ATP5J2 1.368321641
GNB1 1.366417736
DLG4 1.363981591
SH3GLB2 1.36363306
KTN1 1.362629072
RAB3A 1.362173026
(Continued)
Table 7 | Continued
Protein Cortex up Cortex down Hippo up Hippo down
CCT7 1.3567651
SDHC 1.347654394
BCAN 1.342898167
HSPH1 1.337373319
ADD2 1.336930818
AP2A2 1.335723865
DYNLL2 1.322647505
GDA 1.312825433
TKT 1.3105561
COX7A2 1.308575621
SNCA 1.305570043
BAIAP2 1.303596608
SH3BGRL3 1.302583328
NPM1 1.301978732
NIPSNAP1 1.299090793
ARPC4 1.296939524
NAPA 1.292138971
CALB1 1.290893833
CAMKV 1.286413462
COX6C 1.286388519
COX5B 1.285714649
NDUFA9 1.285358088
ATP6V0D1 1.275603048
NSFL1C 1.274526051
LDHA 1.269135901
ATP6V1F 1.266693513
CLTB 1.265664013
SRSF4 1.261593119
LRGUK 1.260891479
NDUFS8 1.260447912
PPP2CB 1.259397109
COX4I1 1.256849924
CAMK2D 1.256848229
DNAJC6 1.255985647
COL6A2 1.253698992
CRYM 1.251866833
PPP3CA 1.249125255
SLC2A1 1.24839376
PPFIA3 1.244596343
CAMK2A 1.241519397
SYP 1.237859198
AP2B1 1.237413188
USP24 1.233820239
FABP5 1.233314773
SEPT9 1.226916013
EHD1 1.226344591
CAP2 1.223807885
SLC25A3 1.221941931
CAMK2B 1.22058499
PTGES3 1.216665914
PRDX1 1.215985447
ATP5I 1.215521395
ATIC 1.213849668
GSTM5 1.213704207
NDUFS7 1.211966939
(Continued)
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Table 7 | Continued
Protein Cortex up Cortex down Hippo up Hippo down
DCLK1 1.207992461
GPD1L 1.207286149
HNRNPL 1.205847041
NAPB 1.202833155
RTN4 1.201798491
PCSK1N −1.245474191
WDR7 −1.245967263
MAG −1.248958157
DDB1 −1.255013637
MOBP −1.256321905
GAD2 −1.26014124
INA −1.265874043
TPT1 −1.268669401
IDH3G −1.270175029
PCCB −1.272883353
MAPRE2 −1.274095945
MRPS36 −1.275342647
MARCKS −1.280485807
PSMC6 −1.281124693
ABAT −1.283265073
NTM −1.284285221
CA2 −1.284359839
HPCAL1 −1.284463003
MOG −1.295178624
PSMA6 −1.297701354
SDHA −1.300775393
COPB1 −1.300938943
NONO −1.301095086
TUFM −1.311237761
ADSS −1.311542644
IGSF8 −1.312784192
COX5A −1.313555144
UQCRFS1 −1.316410553
CKB −1.318123142
PIP4K2B −1.324477494
NEFM −1.330302859
PSMD6 −1.330311752
NEFL −1.344530231
NDUFA8 −1.348309239
BIN1 −1.354260702
PTMS −1.379162453
PHB2 −1.381012946
NDUFS2 −1.382654847
DSTN −1.396469687
CCT5 −1.396711507
S100B −1.403153034
CLASP2 −1.403192685
EPB41L1 −1.419486383
PFKL −1.424253294
PSAP −1.429458675
CPLX1 −1.437904339
SERPINA3K −1.462482626
AHSA1 −1.482509362
SET −1.494218612
ATL1 −1.49652324
(Continued)
Table 7 | Continued
Protein Cortex up Cortex down Hippo up Hippo down
PRKACB −1.501341659
NME2 −1.502355851
ITPKA −1.515605888
NCS1 −1.519434163
EEF1A1 −1.528884517
PLCB1 −1.530645112
ENPP6 −1.542384655
SYNE1 −1.544411246
PCP4 −1.554348855
MBP −1.583600552
NCEH1 −1.612308156
ACSL6 −1.612342183
GLO1 −1.659621805
PPP1R1B −1.668571078
HSD17B10 −1.719780931
SIRT2 −1.776727737
GPHN −1.810243901
MORC1 −1.853643692
SLC6A11 −1.877132951
PDHX −1.878732243
PTK6 −1.89800334
DPYSL5 −1.903465278
HPRT1 −2.333095423
For each specific protein studied fold change values, indicated in the table
below, were generated from the iTRAQ expression ratios of (>1.2 or <0.8) pro-
teins differentially regulated in the BTBR tissues [Cortex, Hippocampus (Hippo)]
compared to WT.
inspection of the coherently-regulated multi-tissue protein set
revealed an exciting and potentially novel functional association
of neuronal Wasp (Wiskott-Aldrich syndrome protein) activity
and ASD (Figures 6C,D). To our current knowledge this is the
first example of such a functional correlation, however it is rela-
tively simple to predict that the molecular activities of this skeletal
remodeling factor could impact a disorder such as ASD in which
a less synaptically plastic neurological system is present.
In conclusion, we found that both the social behavioral phe-
notype and the CNS proteomic profile of this ASD model are
relatively age-resistant. Aged BTBR mice possessed elevations in
hippocampal and cortical synaptic markers that likely play a
role in the etiology of the autistic-like phenotype. Low levels
of BDNF have been found inconsistently in the ASD literature
but more consistently in the aging and Alzheimer Disease lit-
erature (Chadwick et al., 2010b). Diminished mature BDNF in
the aged BTBR hippocampus/cortex were seen along with com-
plementary alterations in the downstream signaling pathways
compared to WT aged mice. These findings in-part reinforce the
potential long-term neuroprotective capacity of the ASD pheno-
type with respect to cognitive aging. It is therefore interesting to
posit that despite lower levels of neurosynaptic plasticity that the
more robust and reinforced neuronal network in ASD pheno-
types may indeed act prophylactically over long periods of time
compared to normal CNS networks that degrade due to unre-
paired damage and synaptic loss. The complex proteotype of the
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Table 8 | Textrous!-based collective analysis of coherently-regulated
BTBR-specific proteins.
Word Cosine similarity Z -score p-Value
Motor 0.524476314 1.869598279 0.030741909
Nonsense 0.478414897 1.693752796 0.045132642
Atrophies 0.4700895 1.661969501 0.048256387
Gtpases 0.468206051 1.65477919 0.048962249
Exons 0.466743056 1.649194013 0.049573817
Growth-associated 0.455961506 1.608034038 0.053917589
Inherited 0.455845768 1.607592194 0.053917589
Gtpase 0.455708175 1.607066915 0.054027184
Autosomal 0.453900108 1.600164382 0.054799292
Polymerization 0.453672232 1.599294435 0.054910301
Optic 0.444664336 1.564905613 0.058791455
Exon 0.437675556 1.538225034 0.062024307
Gtp-binding 0.435679912 1.5306064 0.062884696
Maps 0.427384101 1.498936057 0.066936816
Bundles 0.426675363 1.496230358 0.067326828
Disabilities 0.423470554 1.483995579 0.06890446
Gdi 0.419726975 1.469703976 0.070780877
Brothers 0.419534775 1.46897023 0.070916395
Movement 0.417518799 1.461273977 0.072007721
Acuity 0.417184158 1.45999644 0.072145037
Cytoskeleton 0.414147875 1.448405032 0.073808525
n-wasp 0.412898356 1.443634832 0.074369488
Frameshift 0.411123648 1.436859653 0.075358997
Recessive 0.409375594 1.430186227 0.07635851
Wiskott-aldrich 0.407779814 1.424094126 0.077223236
Actin 0.406644694 1.419760659 0.077803841
Wasp 0.405802073 1.416543842 0.078241464
Gtpase-activating 0.402282931 1.403109057 0.080308419
Recycling 0.395770067 1.378245348 0.084101644
Reorganization 0.391991869 1.363821581 0.086283783
Prenylation 0.389968302 1.356096352 0.087549584
Splice 0.388453273 1.350312529 0.088507991
Missense 0.388195935 1.349330109 0.088668483
Streaming 0.387806369 1.347842888 0.088829191
Apparatus 0.3874916 1.346641219 0.088990116
Pericentriolar 0.387010855 1.344805911 0.089312617
Families 0.386042261 1.341108175 0.089960226
Plexiform 0.385574635 1.339322953 0.090285336
Polysomes 0.383798601 1.332542712 0.091265902
Guanosine 0.383107191 1.329903161 0.091759136
Splicing 0.382666221 1.328219703 0.092089053
Cytoskeletal 0.381993528 1.325651608 0.092419849
Mutational 0.381893517 1.325269803 0.092585576
Coiled-coil 0.381550118 1.323958833 0.092751522
gaps 0.380853905 1.321300948 0.093250682
Depolymerizing 0.380444571 1.319738261 0.093417509
Intellectual 0.378479462 1.312236202 0.094760067
Mutations 0.378323187 1.311639602 0.094760067
Protrusions 0.377199886 1.307351254 0.095606356
Neurofibromin 0.376699229 1.305439931 0.095946424
Actin-binding 0.375976678 1.302681498 0.096287381
Atrophy 0.375377983 1.3003959 0.096800485
Dynamics 0.373862886 1.29461182 0.097660115
Pigmentary 0.373853033 1.294574204 0.097660115
(Continued)
Table 8 | Continued
Word Cosine similarity Z -score p-Value
Neuron 0.370913941 1.283353835 0.099746038
Multidisciplinary 0.369651835 1.27853558 0.100448528
Destination 0.369566192 1.278208627 0.100624713
Cilia 0.368620901 1.274599856 0.101154621
Gtp-dependent 0.367048826 1.268598253 0.102220532
Phosphatidic 0.366734218 1.267397195 0.102577645
Identification 0.366608729 1.266918125 0.102577645
Disability 0.365764506 1.263695196 0.103115013
Muscular 0.365741802 1.26360852 0.103115013
Ciliary 0.364952202 1.260594116 0.103654424
Meshwork 0.364710238 1.259670389 0.103834681
Partners 0.364390606 1.258450149 0.104195878
Inheritance 0.364260066 1.257951798 0.104195878
Scanning 0.363734162 1.255944089 0.104557985
f-actin 0.363367304 1.254543564 0.10473938
Beta-galactoside 0.36316993 1.253790062 0.104921003
Anonymous 0.361144496 1.2460577 0.106382198
Protrusion 0.359889734 1.241267484 0.107302874
Sialyltransferase 0.359831442 1.241044947 0.107302874
Neurofibromatosis 0.359791096 1.24089092 0.107302874
Lipofuscin 0.359746522 1.240720753 0.107302874
Radixin 0.35878958 1.237067503 0.108043541
Proteins 0.358631641 1.236464548 0.108229282
Squid 0.358474059 1.23586296 0.108229282
Screen 0.356102317 1.226808525 0.109911295
Filopodia 0.355914644 1.226092057 0.110099338
Extensions 0.355265349 1.223613288 0.110476114
Lowe 0.355018906 1.222672462 0.110664848
Pre-mrna 0.354335273 1.220062601 0.111232437
Leber 0.354284348 1.219868188 0.111232437
Counseling 0.354132651 1.219289065 0.111422096
x-linked 0.354046801 1.218961323 0.111422096
Cones 0.353920096 1.218477608 0.111611986
Contig 0.353576868 1.217167292 0.111802108
Cryomicroscopy 0.35310173 1.215353389 0.112183046
Amaurosis 0.353046083 1.215140949 0.112183046
Methanothermobacter 0.352545212 1.21322881 0.11256491
Neurofibromas 0.35222224 1.211995824 0.11275619
Endocytic 0.352220725 1.211990038 0.11275619
Pumping 0.351073392 1.207609946 0.113523631
Tail 0.350586481 1.205751097 0.113908745
Dynamin 0.350367829 1.204916365 0.114101651
Syndrome 0.349521708 1.20168619 0.114681764
Endosomes 0.347991562 1.195844656 0.11584828
Blindness 0.34724489 1.19299414 0.116434687
Visual 0.347190286 1.192785679 0.116434687
Cosine similarity scores, Z-scores and probability values (p-Value) were calcu-
lated using collective processing of the 16 coherently-regulated BTBR-specific
proteins in the cortex and hippocampal datasets.
BTBR mice revealed molecular and functional signatures highly
reminiscent of those found in humans with neurodevelopmen-
tal disabilities including ASD. Many of these identified processes
play a role in neurodevelopment based on studies inmurinemod-
els, and give more evidence for proteins that are playing a role
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in neuroprotection allowing for maintenance of cognition in the
aged BTBR mice. Therefore, it is possible that the elevated levels
of various synaptic markers and proteins identified proteomi-
cally such as Picalm, Itsn1, Mobp, Ina, as well as signaling actions
involving Wasp functionality served to protect the aging BTBR
brain against age-related declines in cognition often associated
with decreased BDNF. In the current study we observed a robust
maintenance of cognitive ability despite advanced age that may
be due to unique neurosynaptic architecture and activity in the
ASD phenotype. The role of the associated proteins and synaptic
markers provide a foundation for further investigation into this
intriguing mechanism.
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Figure S1 | Collective Textrous! analysis of differentially-regulated cortical
protein subsets. Functional hierarchical word-clouds were generated from
the upregulated (BTBR:WT iTRAQ ratio > 1.2) (A) and downregulated
(BTBR:WT iTRAQ ratio < 0.8) cortical protein data sets.
Figure S2 | Collective Textrous! analysis of differentially-regulated
hippocampal protein subsets. Functional hierarchical word-clouds were
generated from the upregulated (BTBR:WT iTRAQ ratio >1.2) (A) and
downregulated (BTBR:WT iTRAQ ratio < 0.8) hippocampal protein data
sets.
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